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 The process of transcription is integral in all of life.  Transcription is dependent upon many 
players and moving parts, such as transcriptional activators and coactivators that assemble and 
constitute the transcriptional machine, respectively. Despite the fundamental role of transcriptional 
activator and coactivators, a mechanistic understanding of these binding partners recognizes one 
another is lacking, largely due to their challenging biophysical characteristics. Both activators and 
coactivators are highly dynamic and the protein-protein interactions they form are transient, 
making them difficult study mechanistically and structurally.  Given the role that activator-
coactivator complexes play in healthy and diseased organisms, however, it is vital to understand 
their function. 
 Historically molecular recognition models of activator-coactivator complexes have 
characterized the interactions as largely nonspecific, dictated by unstructured and amphipathic 
transcriptional activators interacting with hydrophobic surfaces within coactivators. However, this 
model does not accurately represent the critical role of activator-coactivator interactions. Recent 
data from our lab and others has shifted the model to one that supports specific molecular 
intermolecular contacts underpinning activator-coactivator PPIs. In two structurally different 
coactivators, highly dynamic regions adjacent to the hydrophobic binding surfaces, for example, 
play a role in recognition of activators and in allosteric communication between binding sites.  
The goal of the work in this thesis was to test this model further through comparing several 
coactivators bearing structurally similar motifs, an Activator Interaction Domain (AcID). 
Specifically, we studied the AcID domains from the Mediator subunit Med25 and a second human 
 xvi 
protein, Prostate Tumor Overexpressed Variant 1 (PTOV1), which contains two tandem AcIDs.  
The key differences between these domains reside in the dynamic regions flanking the primary 
binding surfaces. We show that the AcIDs are capable of recognizing overlapping binding partners 
in vitro, with modest differences in equilibrium binding affinities (up to 4-fold). However, using 
transient kinetics, binding mechanisms of the different AcID motifs revealed some more 
significant differences. Specifically, it was found that each AcID paralog exhibit a distinct 
conformational signature upon binding to a given activator, suggesting that the sequence 
differences in the dynamic substructures of each AcID was indeed playing a role in the recognition.   
A second role of the dynamic substructures is in allosteric communication. In the context 
of the AcID paralogs examined here, allosteric communication between two binding sites was 
observed via transient kinetics.  Consistent with this model, we show that a covalent allosteric 
modulator attenuates binding the PTOV1 AcID more potently than Med25 AcID, demonstrating 
the changes in the dynamic regions alters small molecule binding. These dynamic substructures 
can be exploited as hotspots for targeting, as these allosteric regions are not as highly conserved 
in paralogs. We demonstrate that identified allosteric modulators can be used as chemical probes 
to perturb the dynamic hotspots, providing an opportunity to target homologous proteins with high 
selectivity. Further, we show that even highly related activators are able to induce differential 














Molecular Recognition Models and Allostery of Transcriptional Coactivators 
1.1 Abstract 
Transcription is the central process that helps maintain normal cell function in all living 
organisms. This process is tightly regulated through a series of protein-protein interactions at the 
genomic loci. Recruitment to the genomic loci is mediated via DNA-bound activators that can bind 
the activator binding domain (ABDs) of coactivators. These ABDs are central hubs that relay 
information to the rest of the transcriptional machinery. The nature of these interactions has long 
been debated, with early models of molecular recognition arguing for a nonspecific model driven 
by electrostatics and intrinsic disorder of the activator. However, emerging evidence shifts this 
argument towards a more specific model; that is dynamic regions in coactivators undergoing 
unique conformational shifts upon binding to different activators. Moreover, these dynamic 
substructures can dictate allosteric communication within the ABD.  
In this chapter, we explore the models of molecular recognition and allostery that underpin 
coactivator binding. The transient nature of these interactions are discussed in detail, specifically 
how the transcriptional machinery can be organized. Lastly, we explore how dynamic 






1.2 Introduction  
Transcriptional protein-protein interactions (PPIs) are highly regulated due to their integral 
role in gene expression.   These PPIs are responsible for the assembly of transcriptional machinery 
in response to developmental and environmental signals.  These signals prompt transcriptional 
activators to localize to enhancer or promoter regions, and bind to coactivators.1–3  Once the 
complex is formed, the coactivator acts as a bridge, relaying information from the genomic loci to 
the rest of the transcriptional machinery, thus initiating transcription (Fig. 1.1).3,4 Dysregulation of 
transcriptional PPIs results in a variety of diseases, such as cancer metastasis, hypoxia, and 
inflammation.5–8 Despite interest in pursuing transcriptional PPIs as a therapeutic target, these 
interactions are challenging to study as they are not amenable to traditional structural and 
biophysical techniques due to intrinsic disorder and highly dynamic regions.9–11  
Figure 1.1: General mechanism of transcriptional activation. Upon signal transduction and localization of the 
activator to the promoter/enhancer site through the DBD, chromatin remodeling enzyme unwind histone bound DNA, 
revealing the genomic loci. The TAD interacts with the ABD of the coactivator. This complex then recruits the rest 






Recruitment to the genomic loci is mediated by transcriptional activators, binding to DNA 
directly through a DNA binding domain (DBD). Localized to the promoter and enhancer regions, 
activator•coactivator PPIs are formed from amphipathic regions within the activator referred to as 
transcriptional activation domains (TADs) and conformationally dynamic regions of the 
coactivator called activator binding domains (ABDs).1,3 Because of their dynamic nature, 
coactivators act as central hubs at the site of transcription, binding to multiple partners in order to 
relay information to recruit the rest of the transcriptional machinery.4  For example, the master 
coactivator complex CREB binding protein (CBP) consists of seven individual coactivator motifs 
that are linked dynamic intrinsically disordered regions, allowing for a highly flexible protein. The 
domains within CBP interact with hundreds of activators, aided by the overall malleability of the 
protein (Fig. 1.2a).13,14  
Figure 1.2: Coactivator complexes and their ABDs. A). Gene layout of the master coactivator CBP. The individual 
domains in CBP are linked by long, flexible linker regions, resulting in high levels of conformational plasticity. 
Highlighted in dark gray are coactivator ABDs that bind directly to transcriptional activators. In light gray are 
coactivators that act as chromatin remodelers, such as a histone acetyltransferase domain (HAT) and a 
bromodomain.13,15 B). Mediator complex and its Med25 subunit. The Mediator complex is another excellent example 
of a coactivator complex. Within the tail module of Mediator are dozens of coactivators, such as Med25. Within 
Med25 is its VWA domain that links it to the rest of the Mediator complex, its ABD domain termed AcID and a 





Coactivators act as hub proteins, and they are critical in connecting all the key players of 
transcription.4,16 One such example is the coactivator complex named Mediator. Mediator is 
comprised of four units, the head, middle and tail modules, and a removable kinase domain, acting 
in concert as a coactivator complex.12,19 Mediator itself binds to RNA Pol II,  acting as an 
intermediary between transcriptional activators bound to DNA and the rest of the general 
transcription machinery.4 Located within the tail region are coactivator subunits such as Med25. 
Med25, connected to the Mediator complex through its von Willebrand factor A domain (VWA), 
is able to interact with other coactivators, such as CBP, and a multitude of transcription factors 
(Fig. 1.2b).12,18 It is through these interactions that information is relayed through the preinitiation 
complex.  
1.3 Transcriptional activators in activator-coactivator complexes 
The mechanisms by which activators and coactivators recognize each other have long been 
argued.18,20–22 Early models were largely nonspecific, arguing that the gene-specific function of 
activators was due to the DNA binding domain recognizing particular DNA sequences. 
Biochemical and biophysical studies indicated that activator TADs were unstructured when 
unbound.20–22 Additionally, the only identifiable sequence patterns among TADs were the presence 
of acidic and hydrophobic residues; further, virtually any amphipathic peptide could function as a 
TAD when localized to DNA (Fig. 1.3).1,9,23,24  One leading example is the promiscuity of 
activators such as the herpes simplex viral protein 16 (VP16) which was found to bind to a variety 
of different coactivators and also to function in all eukaryotes.25,26   Structural studies then revealed 
that TADs, once termed “acidic blobs and negative noodles” undergo a coupled folding and 
binding, often taking on an amphipathic helical structure when bound to a coactivator, changing 
the viewpoint of models to argue for specificity.20,27,28 
 5 
Unfortunately, the discovery that not all TADs form ordered complexes upon binding 
caused the molecular recognition model to shift back to one of non-specificity.10,29 It has been 
shown that some TADs can bind to the ABD binding face in multiple distinct orientations, or even 
to different binding sites all together, thus supporting the argument that there are no specific 
recognition motifs within TADs themselves.30  A well-cited example of this is the coactivator 
Med15’s binding partner Gcn4. The Gcn4 TAD was shown to bind to all of Med15’s ABDs in 
multiple orientations, in what has been described as a TAD “hydrophobic cloud.” None of these 
models take into consideration, however, any role the coactivator may serve in molecular 
recognition.31,32  
Figure 1.3: Models of molecular recognition. The model for the mechanism of which activators•coactivator 
interactions occur is largely contested. The original hypothesis suggested one of largely nonspecific interactions, with 
intrinsically disordered, negatively charged TADs binding to coactivators. Recent biophysical and structural data 
suggests this model is oversimplified. In addition to TADs existing in conformational ensembles, often experiencing 
coupled folding upon binding, but the ABD domain also undergoes conformational changes due to internal 





While it has been well-accepted that TADs undergo a coupled folding and binding, it has 
largely been ignored that the ABD can also undergo significant conformational changes. As 
described in more detail in section 1.4, biophysical studies have demonstrated that coactivators 
can adopt unique conformations themselves when binding to different activators, suggesting that 
ABDs can adapt to each TAD (Fig. 1.3).27,33 The kinase-inducible domain interaction domain 
(KIX) of CBP is a prime example of an ABD undergoing a significant remodeling event. Upon 
binding of MLL, KIX is shown to undergo repacking of its hydrophobic core, stabilizing the loop 
region of the MLL binding site.34 This ultimately stabilizes interactions with TADs to the other 
binding site, such as cMyb, by almost two-fold. In fact, binding of one TAD to KIX can 
significantly influence which binding partners interacts with the other site, thus demonstrating that 
conformational changes upon binding can influence function and selectivity.35–37  
1.4 Phase separation of transcriptional components 
It is critical that the process of transcriptional machinery assembly is rapid and reversible, 
and thus it is underpinned by transient, short-lived interactions. The transient nature of these 
interactions allows for expression to be turned on and off in a temporally and spatially appropriate 
manner.38 One model proposed that this process is mediated is through phase separation. At its 
core, phase separation is a physiochemical process by which molecules separate into a dense phase 
and a depleted phase, allowing for rapid phase transitioning. Phase separation is a well-studied 
phenomenon in cells given their colloidal nature (Fig. 1.4).39 Cells use phase separation as an 
organization tool, creating biomolecular condensates that can compartmentalize and concentrate 
biochemical reactions as well as allow for rapid movement of compartments into and within in the 
dense phase.39,40  
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Proteins can undergo phase separation, with a variety of factors leading to their propensity 
to undergo phase transitioning, including concentration, multivalency and solubility.  Intrinsically 
disordered proteins, like TADs, have been found to have a high propensity to undergo phase 
separation.40,41 Moreover, phase separation has been observed at the site of super-enhancers, long 
stretches of enhancers that are often responsible for regulating genes controlling cell differentiation. 
Specifically, super-enhancers are known to concentrate and compartmentalize transcriptional 
machinery, with the multivalency of transcription factors enabling to supposed crosslinking and 
ultimately leading to phase separation.42,43  
Figure 1.4: Phase separation as an organization tool for transcription. Phase separation is a proposed method for 
organization and the rapid assembly of biomolecules.  As protein concentration increases, rising above the critical 
concentration, solubilized protein can form into liquid droplets, called biomolecular condensates. These droplet 
compartments allow for rapid diffusion of protein within the condensate and promotes dynamic exchange with the 
dilute phase.39  
 
One early example for the evidence of phase separation at transcription is interaction 
between coactivator Med1 and activator BRD4, both of which contain intrinsically disordered 
regions. Med1 and BRD4 were found to localize to puncta within the nucleus, and these puncta 
were traceable to genes known to be regulated by super-enhancers. Extensive biophysical and 
biochemical analysis demonstrated that these puncta are not membrane-bound, suggesting they 
exist as biomolecular condensates close to the site of transcription. Further, Med1 and BRD4 were 






disordered region concentrates were found to activate transcriptional machinery from nuclear 
extracts.44 
The phase separation model for transcriptional regulation suggest that phase separated 
liquid droplets are highly concentrated in transcriptional machinery. Transcription initiation would 
greatly benefit from highly concentrated biomolecular condensates. For example, CBP/p300 is 
known to be nonabundant in the nucleus, and if found to exist in phase separated droplets, could 
allow for the quick localization to the site of transcription. Essentially, the physical consequences 
of phase separation lead to hyper-cooperativity, with a sort of switch-like behavior, and can cause 
high frequency transcriptional bursting. This behavior can help accommodate the short-lived, 
transient nature of activator•coactivator interactions, allowing for rapid assembly and disassembly 
at the site of transcription.43,45 However, there has not been direct evidence of phase separation in 
a biological system, and has yet to be observed at non-super-enhancer regions.  
1.5 ABDs are the molecular recognition units  
While phase separation can accommodate the short-lived nature of these interactions, it 
does not account for molecular recognition. Moreover, the molecular recognition model that 
activator•coactivator binding mechanism is non-specific does not account for the critical role these 
PPIs play in gene regulation. While TAD promiscuity is often argued as a driving force, as seen 
with VP16 or p53, promiscuity is often studied in isolation on individual domains.25,26  This is 
partially due to the fact that is often technically impossible (or nearly so) to study full length 
systems in vitro, resulting in the use of truncated domains and therefore not accurately 
recapitulating biological systems.46,47 Moreover, the nonspecific model does not take into 
consideration other components of the transcriptional machinery ensemble, specifically 
coactivators. Coactivators bind to tens of different binding partners, each resulting in different 
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gene expression. The KIX domain of CBP binds to dozens of different partners, (Fig. 1.5), 
initiating genes responsible for a diverse array of different pathways.14 Co-localization does not 
explain ABD molecular recognition, as these dynamic motifs need to be able to quickly bind, 
recognize, and initiate gene-specific transcription, then advance to the next gene.   
Figure 1.5: The two binding faces of CBP GACKIX and its interaction partners. GACKIX consists of two binding 
faces, termed the cMyb binding face and MLL binding face. As illustrated, GACKIX binds to a suite of different 
binding partners implicated in a variety of networks and diseases.13,14  
 
It is becoming increasingly accepted that ABDs within the coactivators serve as molecular 
recognition units. The KIX domain, for example, is one of the most important molecular 
recognition sites for PPIs at gene regulation.  The KIX motif has been identified in a multitude of 
coactivators, such as CBP/p300, the human activator recruited cofactor Arc105, and Med15 of the 
yeast Mediator complex.14,48,49  KIX motifs are responsible for recognizing a range of transcription 
factors, with each interaction playing a critical role in a variety of biological pathways, including 
long term memory storage in the hippocampus, lipid homeostasis in mammals, and even 
processing of HIV-dependent binding partners.14,49–51 
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Figure 1.6: Structures of transcriptional coactivators ABDs. Typically, ABDs are helical bundles connected by 
dynamic lo0p regions. Excellent examples of this are the KIX domains found in CBP/p300, and Med15 subunit of the 
yeast Mediator complex. TAZ1 and TAZ2 are two other coactivators of the CBP complex. Lastly, the Med25 subunit 
of the human Mediator complex contains a seven-stranded β-barrel core, shown in gray, flanked by more common 
structural features: α-helices and loops.15,18,35 
 
These ABDs often are helical motifs, as observed with the individual coactivator domains 
found within CBP/p300 (Fig. 1.6). These helical motifs are linked by loop regions, thus allowing 
for a highly dynamic protein capable of adopting many different conformations. In fact, the 
dynamic, helical nature of ABDs plays a crucial role in the physical binding of activators and 
coactivators.5,13,52 While ABDs typically lack topography with obvious binding sites, the malleable 
nature of ABDs allows for them to adopt conformations specific to each binding partner with the 
interaction stabilized by hydrophobic and electrostatic interactions.53  In contrast to this,  and of 
importance to the work in this thesis, is the structurally distinct ABD of Mediator subunit Med25, 
termed the Activator Interaction Domain (AcID), possessing a seven-stranded β-barrel serving as 
the core of the domain. However, similar to prototypical ABD structures, Med25 AcID is flanked 
by three α-helices and flexible loop regions (Fig. 1.6).18,54 
1.6 Hotspots and allostery within ABDs  
While the activator•coactivator PPI interface is rather featureless, lacking any defined 
binding pocket and binding taking place over large surface areas, adjacent dynamic substructures 
also play an important role in molecular recognition.46 These hotspots can help regulate internal 
CBP GACKIX 







 Med25 AcID  
PDB: 2XNF  
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allosteric networks upon when a  conformational change is induced upon at non-overlapping 
sites.46,55  This is observed in ABDs and is a direct result of ABD malleability.56 Proteins in their 
native state exist in essentially a conformational ensemble with pre-existing populations of 
different states become redistributed upon binding and a resulting allosteric perturbation.57,58  
Figure 1.7: Different conformations of CBP GACKIX. A) Different binding partners of KIX result in different 
conformation and can even result in overall stability of the protein. cMyb, mLL and pKID are all TAD binding partners, 
and can form ternary complexes via cooperative binding. Fragment 1-10 is an allosteric modulator that tethers to 
N627C, changing cooperativity of KIX binding. B) Structural overlay of the different KIX conformations. In red is 
MLL and pKID bound, green is c-Myb bound and purple is 1-10 bound. The biggest changes in conformation can be 
observed in the loop regions.  
 
The presence of dynamic regions allows for communication within coactivators. Upon 
binding at one interface, a conformational change is induced, which can change binding at 
secondary sites.56,57  The previously described CBP KIX is a key example of this (Fig. 1.7). Not 
c-Myb Bound Structure
PDB ID: 2AGH







only does binding to one face result in cooperative binding to the other face but binding to both 
faces causes an overall stabilization of the ABD. In its native state, KIX, and other ABDs, 
essentially exists in a conformational ensemble. Once KIX binds to another protein or peptide, it 
is shown to undergo a winnowing of conformational ensembles, resulting in a stabilization.33,37,48  
Another example of ABD restructuring is observed with another CBP ABD, TAZ1. Binding of 
CITED2, a negative regulator of hypoxic stress response, to a TAZ1 to a secondary site results in 
a conformational change in TAZ1 that inhibits binding of a second TAD, HIF1α. Put another way, 
through a forced competitive mechanism, CITED2 binding to the ABD results in a restructuring 
that destabilizes HIF1α binding (Fig. 1.8).22 These observations demonstrate that ABD remodeling 
is critical component that needs to be considered in molecular recognition, and a guiding factor in 
the work presented in this thesis. 
 
Figure 1.8: Schematic for the displacement of HIF1α. TAZ1 is shown in gray, HIF1α is in 
orange, and CITED2 is in blue. Rather than trying to outcompete the tight interaction of HIF1α, 
CITED2 binds to an allosteric site. Binding to the second site induces a change in the dissociation 
rate of HIFα, enhancing it by an order of magnitude.22 
 
Due to their role in allosteric regulation of ABDs, dynamic substructures serving as hot spots 
can be exploited for targeting.46,55 Given the inherently difficult nature of targeting PPIs, use of 
allosteric modulation is promising.11  Typically, PPI interfaces are highly hydrophobic and often 
conserved, making it difficult to target orthosterically while achieving selectivity and specificity.  
Use of allosteric modulators that can bind to dynamic hot spots can induce conformational changes 
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that can inhibit or enhance binding.59  Allosteric modulators that target dynamic hot spots can act 
as chemical probes that can be used to dissect binding mechanisms.11,47,60 Additionally, given that 
dysregulation of these PPIs often results in disease, it is critical to understand binding mechanisms 
as well as be able to selectively and specifically target.  
KIX is a prime example of an ABD present in multiple systems, therefore increasing the 
difficulty in selective modulation. Using a tethering screen approach, the fragment 1-10  was found 
to target CBP GACKIX N627C with high affinity (Fig. 1.8).59 This allowed for the development 
of irreversible chemical cochaperones that are specific to CBP KIX over its paralog p300 KIX. 
Not only was 1-10 was found to cause allosteric enhancement of a pKID binding, 1-10 derivatives 
were able to induce conformational changes that either positively or negatively impacted 
cooperativity.36  
Over the last decade, there has been a critical reevaluation of the mechanism models of 
activator•coactivator interactions. Once proposed to be non-specific and driven by electrostatics, 
the paradigm is shifting to one of more specificity. Conformational changes of the ABD upon TAD 
binding can result in a winnowing of conformational ensembles from the native to bound state. 
The conformational rearrangement is driven by dynamic substructures. Additionally, there exists 
an allosteric network, influenced by these conformational changes. However, there is still much to 
be discovered about this process. The work outlined in this thesis aims to expand upon the model 
of ABD conformational changes by demonstrating that coactivators are linked via a common 
mechanism. Specifically, the malleable nature of ABDs can induce conformational changes upon 




1.7 Dissertation summary  
The goal of this dissertation was to explore the binding mechanisms the activator binding 
domain AcID utilize. Deviating from prototypical coactivator structures, the AcID motif contains 
a seven-stranded β-barrel core in addition to its loop and helical substructures. Recent work has 
indicated that despite the rigid core, AcID interactions with activators can be dynamic due to the 
presence of dynamic loops and helices.61 Using three different AcID containing systems, Med25, 
PTOV1A and PTOV1B, each with key residue differences in their dynamic substructures, we set 
out to determine how these changes affect ABD plasticity and their role in molecular recognition.   
In chapter two, we use a biophysical approach to determine how different AcID motifs 
recognize activator binding partners. We start establishing the changes in sequences and how this 
affects predicted structures. Using this information, we set out to determine if activator binding is 
conserved, and how this affects conformation and binding mechanisms.  
In chapter three, we examine how hotspots can be exploited in a two-pronged approach. To 
begin with, we use the highly similar ETV/PEA3 family of activators to examine selectivity. 
Specifically, we set out to see how slight changes in sequence of the activator can affect 
conformational changes, driven by in coactivators. We would predict that such small changes 
would not significantly alter mechanisms. We then explore allosteric communication in 
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Sequence Differences within Dynamic Regions of AcID Motifs Alter Conformation of 
Complexes with Activators * 
2.1 Abstract 
Activator binding domains (ABDs) are the molecular recognition units of transcriptional 
coactivators, allowing for a single protein to interact with a diverse array of transcriptional 
activators. While most ABDs are helical bundles, one ABD stands out with a distinct structure-the 
Activator Interaction Domain (AcID). AcID, found in Med25 and PTOV1, consists of a seven-
stranded β-barrel flanked by dynamic substructures including helices and loops. Recent work in 
our group has demonstrated the role of these dynamic substructures in molecular recognition of 
distinct activator binding partners. That is, the dynamic loops and helices allow for Med25 AcID 
to access unique conformations in response to each binding partner.  Our objective was therefore 
to determine how sequence changes in the dynamic regions of three AcID paralogs ultimately 
affects binding. Using a biophysical approach, we determine how sequence deviations alter the 
binding affinities, mechanisms and conformations of the AcID motif. We demonstrate that, despite 
high sequence homology, there is a loss in secondary structure of the PTOV1 AcIDs, as well as a 
decrease in thermal stability. Despite the changes in sequence of the dynamic regions and structural 
instability, however, all three AcIDs are capable of recognizing the same binding partners with 
only moderate changes in affinity. Further, using transient stopped-flow kinetics, we observed the 
binding modes of the different AcID motifs. Specifically, despite being paralogs, we show 
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different binding modes for each AcID motif, suggesting that changes in the overall dynamic 
regions are specific to each AcID without changing overall binding affinities.  
2.2 Introduction  
 
The transient protein-protein interactions (PPIs) formed between transcriptional activators 
and coactivators plays an essential role in the initiation of transcription.1,2 Coactivators generally 
act as hubs in transcriptional initiation, interacting with DNA-bound transcriptional activators and 
with other coactivators to assemble the transcriptional machine.3,4 A single coactivator is capable 
of recognizing a variety of transcriptional activators using its activator binding domain (ABD). 4,5 
Dysregulation of these PPIs can result in a variety of disease states, including oncogenesis, viral 
infection, and tumor metastasis.6–9 Although there have been many biophysical studies of ABD 
PPIs, general molecular recognition principles for complex formation have only recently begun to 
emerge.10–12 These principles are critical for both understanding transcription and for the discovery 
of small molecules that modulate PPI networks.  
Most often, ABDs are comprised of helices connected by dynamic loops.11  In contrast, the 
coactivator Med25 contains an ABD that deviates from the helical bundle model, instead 
containing a core seven-stranded β-barrel flanked by three alpha-helices (Fig. 2.1). This ABD is 
the Activator Interaction Domain (AcID).  Previous work by others suggested that the β-barrel is 
where most of the interactions with activators occur.14,15 In contrast, recent work in the Mapp lab 
indicates that the β-barrel may serve as a central scaffold, but the dynamic loops and helices 
flanking the barrel make critical and specific contacts with activators (Fig. 2.1).11  
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Figure 2.1: Dynamic substructures of ABDs make critical contacts with binding partners. On the left is Med25 
AcID, comprised of a seven-stranded β-barrel flanked by three α-helices and loops. While having a β-barrel scaffold, 
it still contains dynamic substructures. On the right are the different conformations of CBP GACKIX when bound to 
different binding partners. The biggest changes in shape are observed in the top loop region.16,17   
 
The work in this chapter aims to dissect how dynamic substructures affects molecular 
recognition within AcID motifs. Specifically, we look at paralogs of AcID, found in Med25 and 
PTOV1, a second protein in humans that contains two tandem AcID motifs.18,19  These proteins 
share high sequence identity, 81% and 71% respectively to Med25 AcID, but deviate in sequence 
in their dynamic regions (Fig. 2.2).  Using a biophysical approach, we explore how these sequence 
deviations alter the binding mechanisms in complexing with transcriptional activators. The guiding 
hypothesis was that the sequences differences would influence binding selectivity and also the 
conformational changes of the resulting complexes.  In the former case, this can be tested by 
measuring the equilibrium binding affinities for a panel of activators. In the latter, transient kinetic 
studies can provide insight into the conformational changes that might occur with complex 
formation. We show that while overall the binding affinities and mechanisms are conserved, we 
see a loss in conformation states. While not the original hypothesis, these results demonstrate that 
each AcID paralog demonstrates a unique set of conformations, suggesting there is a degree of 
specificity in binding. 
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Figure 2.2: Sequence alignment of the AcID paralogs. A) Shown in yellow are the sequences differences. Boxed 
are the dynamic substructure regions.  Sequence alignments of the AcID homologs reveals that PTOV1A shares 81% 
sequence identity to Med25 AcID, and PTOV1B shares 71% identity. Specifically, while there are some deviations, 
the b-barrel remains largely conserved. In contrast, residue deviations, such as charge flips and loss of charges, are 
found in the dynamic loop and helical regions. B) Sequence deviations of PTOV1A (right) and PTOV1B (left) mapped 
onto Med25 AcID’s two binding faces. Circled in red are the loops and helices that are implicated in binding.  
 
 
2.3 Results and Discussion  
2.3.1 Structural characterization of the AcID paralogs reveals loss in secondary structure 
Figure 2.3: Structures of the AcID motifs. Med25 AcID’s structure was solved via NMR and is shown to have a β-
barrel flanked by three α-helices (PDB 2XNF).14 Threading models predict the structure of the two PTOV1 AcIDs. 
The overall barrel region is conserved, while there appears to be a loss in secondary structure, specifically with the 
helices, resulting in more dynamic loops.20  
 
Previous work has determined that Med25 AcID is comprised of a core seven-stranded β-
barrel flanked by three α-helices and loops. While there are no structures of the PTOV1 AcID 
Med25 AcID PTOV1B PTOV1A  
Loop 1 Loop 2 
Helix 1 Helix 2 Loop 3 
Loop 4 Helix 3
Med25_AcID       --SVSNKLLAWSGVLEWQEKPKPASVDANTKLTRSLPCQVYVNHGENLKTEQWPQKL-IM
PTOV1A           ---LSNKLLAWSGVLEWQEKRRPYS-DSTAKLKRTLPCQAYVNQGENLETDQWPQKL-IM
PTOV1B           VQIVNNKFLAWSGVMEWQE-PRP---EPNSRSKRWLPSHVYVNQGEILRTEQWPRKL-YM
                     
Med25_AcID       QLIPQQLLTTLGPLFRNSRMVQFHFTNKDLESLKGLYRIMGNGFAGCVHFPHTAPCEVRV
PTOV1A           QLIPQQLLTTLGPLFRNSQLAQFHFTNRDCDSLKGLCRIMGNGFAGCMLFPHISPCEVRV
PTOV1B           QLIPQQLLTTLVPLFRNSRLVQFHFT-KDLETLKSLCRIMDNGFAGCVHFSYKASCEIRV
               
Med25_AcID       LMLLYSSKKKIFMGLI-PYDQSGFVNGIRQVITN--
PTOV1A           LMLLYSSKKKIFMGLI-PYDQSGFVSAIRQVITTRK
PTOV1B           LMLLYSSEKKIFIGLI-PHDQGNFVNGIRRVIA---
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motifs, threading models created by I-TASSER demonstrate an overall structural conservation in 
the β-barrel, with a slight loss in structure in the helices (Fig. 2.3).20 However, circular dichroism 
(CD) scans suggests loss in the barrel region for the A and B domains at 208 nm, as well as a slight 
loss in other secondary structures at 220 nm, consistent with threading models (Fig. 2.4).   
Figure 2.4: CD scans of the AcID motifs. Illustrated above are the collected CD spectra of the A (Red) and B (Green) 
AcID domains in PTOV1 and Med25 AcID (Blue). The β-barrel, appearing at a wavelength of 209 nm, appears more 
conserved than the helical reigons, measured at 222 nm. Data was obtained by Olivia Pattelli and Dr. Matthew 
Beyersdorf.  
 
In order to determine protein stability of the AcID homologs, CD thermal scans were 
conducted to determine the melting temperature.  Thermal melts were conducted and monitored at 
222 nm and 208 nm. Med25 AcID has a melting temperature of approximately 70 ̊ C. Despite high 
sequence identity with Med25 AcID, PTOV1A and PTOV1B had melting temperatures of 61 ˚C 
and 66 ˚C respectively.  Med25 AcID’s thermal melt displayed two phases, with the first phase 
corresponding to the fraying of the helices, and the second phase corresponding to the barrel 
unraveling.  Only one phase was observed for PTOV1A and PTOV1B. Taken together, these data 
suggest there is a loss in secondary structure in the PTOV1 AcID motifs comparatively to Med25 
AcID.  Given that PTOV1 appears to be more unstructured than Med25, and has a lower melting 
temperature overall, we predicted that it would be difficult to observe conformational changes of 
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2.3.2 Activators preferentially bind to individual activator paralogs 
Figure 2.5: The two binding faces of AcID interact with different binding partners. Binding site A, termed the 
H1 face, interacts with ERM from the ETV/PEA3 family of transcription factors as well as one of the two N-terminal 
TADs of VP16.14,21  Binding site B, termed the H2 face, binds to the second VP16 TAD as well as ATF6α, responsible 
for hypoxic stress response.14,22  
 
We wanted to test if the different AcID paralogs bound to the same binding partners, and 
if so, with what affinity.  PTOV1A and PTOV1B were tested against Med25 AcID’s TAD binding 
partners in an equilibrium binding experiment (Fig. 2.5). More specifically, we used the TADs 
VP16, ERM, and ATF6α. ERM belongs to the ETV/PEA3 family of transcription factors and is 
implicated in cancer metastasis.7,21,23,24 The herpes simplex protein VP16, which contains two 
tandem TADs that bind to both faces of AcID is responsible for activating transcription of viral 
genes during an infection.8 Lastly, ATF6α is an endoplasmic reticulum stress response 
transcription factor involved in the unfolded protein response under hypoxic conditions.22  
The-FITC-labeled TADs were tested against the PTOV1 AcID motifs via fluorescence 
polarization (FP) assays  (Table 2.1). The activators were all observed to bind to PTOV1A/B, 
which is not surprising due to the high degree of sequence conservation in the β-barrel. Prior work 
in our lab suggests that the β-barrel plays a significant role in binding partner affinity. However, 
there were differences in the exact values. Of note is the difference in ATF6α’s affinity for 
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PTOV1A and PTOV1B. There is a significant difference in affinity, with PTOV1A having almost 
6-fold affinity over PTOV1B. This is likely due to the Lys-rich loop located on the H2 binding 
face, the binding site of ATF6α. This loop has been demonstrated to be highly critical for activator 
binding. In Med25 AcID, there are three consecutive Lys residues, conserved in PTOVA, located 
on the H2 binding face, the binding site of ATF6α. This Lys-rich loop has been demonstrated to 
be highly critical for activator binding. In Med25 AcID, there are three consecutive Lys residues, 
conserved in PTOV1A. In PTOV1B, however, the last Lys is a Glu residue. This alters the 
surrounding electrostatics with the change of charge in the loop. As discussed below, electrostatics 
play a critical role in binding affinity (Fig. 2.6). 
Table 2.1: Apparent equilibrium Kd’s. Kd values were measured using fluorescence polarization assay. Serial 
diluted protein was complexed with 20 nM FITC-labeled peptide.  Data is in triplicate and the error is reported as 
SDOM.  
 MED25 PTOV1A PTOV1B 
ATF6Α 0.52 ± 0.6 µM 0.20 ± 0.01µM 1.2 ± 0.2 µM 
ERM 0.59 ± 0.02 µM 0.42 ± 0.04 µM 0.43 ± 0.03 µM 
VP16 0.06 ± 0.004 µM 0.03 ± 0.002 µM 0.02 ± 0.005 µM 
 
Figure 2.6: Key differences and binding curves of the AcID motifs with ATF6α. On the left is Med25 AcID with 
the triple Lys loop circled in red. K520 is a Glu residue in PTOV1B (shown as the red side chain). On the right are 
the three binding curves for Med25 AcID, PTOV1A and PTOV1B.  PTOV1B has almost 6-fold affinity for ATF6α 
over Med25 and PTOV1A, which is likely due to the residue changes in the Lys-rich loop on the H2 face.  
 
ATF6a














































  28 
Additionally, VP16 demonstrates a higher affinity for PTOV1A and PTOV1B over Med25 
AcID. VP16 binds to both the H1 and H2 faces, using its two N-terminal TAD regions with an 
intrinsically disordered linker that wraps around the β-barrel to contact both faces (Fig. 2.7).  The 
loss in affinity may be due to the loss in secondary structure, as shown by the predicted structures 
and CD data (Fig. 2.3 and 2.4). With less secondary structure, VP16 can wrap and contact both 
sites easier and create more points of contact, resulting in a higher binding affinity. Additionally, 
there is an increase in hydrophobic residues, particularly on the H1 face for PTOV1A and PTOV1B. 
Residue M470 is a Leu, thus increasing the overall hydrophobicity in the groove VP16 binds to on 
the H1 face.  
 
Figure 2.7: Binding curves of the AcID motifs with VP16. VP16 binds to the PTOV1 AcID motifs with a tighter 
binding affinity than to Med25 AcID. This is likely due to the loss in secondary structure, allowing VP16 to wrap 
around the barrel region and have more contact, thus increasing the binding affinity.  
 
2.3.3 Transient stopped-flow kinetics offer insight into PTOV1A complex formation 
Electrostatics play an important role in initial binding of TAD•ABD interactions (Fig 2.8).  
Data generated by Dr. Nicholas Foster in the Mapp lab demonstrates that increasing NaCl 
concentrations attenuates TAD affinity for Med25 AcID. Additionally, salt ions can play a critical 
role in binding affinity. Specifically, the use of Mg2+ cation was shown to critically affect activator 
binding to Med25 AcID, showing a 13-fold decrease in activator binding over Na+.  However, 
electrostatics alone do not dictate binding, as recent data has shown that conformational changes 
within the coactivators driven through dynamic regions can modulate molecular recognition.10,11  
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Figure 2.8: The role of electrostatics in activator binding. A) The Hofmeister Series is a classification of how 
different ions affect protein interactions. B) FP traces demonstrating how different salt ions affect binding. Not only 
does higher NaCl concentrations attenuate binding, but the type of ion can greatly alter binding as well. Data was 
collected and analyzed by Dr. Nicholas Foster.  
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To test this hypothesis, transient stopped-flow fluorescence spectroscopy was utilized to 
examine the underlying mechanistic features of PTOV1A in comparison to Med25 AcID using the 
VP16, ERM and ATF6α TADs (see Methods for details). By determining the association 
mechanism of PTOV1A•activators, we can calculate the dissociation constant, microscopic rate 
constants, and rate and equilibrium constants associated with conformational changes. The system 
was originally developed by Dr. Matthew Henley for Med25 AcID. In order detect activator-
coactivator interactions, the environmentally sensitive fluorophore 4-N,N-dimethylamino-1,8-
napththalimide (4-DMN) was used. 4-DMN, conjugated to β-alanine, was incorporated to the N-
terminus of the TAD activators.11  For the work discussed this thesis, the system was further 
optimized for detection of PTOV1A. Figure 2.9 depicts the overall experimental layout.   
Figure 2.9: Design of the transient stopped flow experiments. On the left depicts how we measured kon. Increasing 
concentrations of protein were rapidly mixed with DMN-labeled tracer and fit using the equation outlined in the 
methods section below. For the koff experiments (right), protein was precomplexed with DMN-labeled peptide and 
competed off using unlabeled peptide.  
 
ERM binds to the H1 face of PTOV1A with a distinct conformational ensemble  
Analysis of HSQC NMR data has revealed that ERM, a member of the ETV/PEA3 
transcriptional activators binds to the H1 binding face of Med25 AcID. Specifically, ERM was 
found to localize to a groove on the H1 binding face, with predominate perturbations on α3 and β5 
(Fig. 2.10).21 Mutations to residues R538, Q451, and K411 inhibit ERM binding, but left H2 
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binding largely unaffected.11 Interestingly, residues R538 and Q451, located on α3 and β3 
respectively, are conserved in PTOV1A. K411, located in the loop between β1 and β2, is changed 
to an Arg residue in PTOV1A, thus maintaining a positive charge, but the terminal amino is 
removed. Additionally, changes in neighboring residues, such as K440 to a Glu residue cause a 
change in charge (Fig. 2.2). We hypothesized that due to the deviations of the dynamic regions in 
PTOV1A, there will be distinct changes to the conformations observed.   
ERM•Med25 rate constants were determined using global fitting in Kintek Explorer and 
an “inverted” association experiment in order to validate the three-step mechanism observed.   
PTOV1A was, on the other hand, shown to undergo complex formation within the timescale of 
the instrument. Figure 2.11 shows the association and dissociation experiments. PTOV1A had a 
kon two-fold faster than Med25 AcID, 780 µM-1s-1 and 300 µM-1s-1 respectively, but showed very 
similar dissociation constants, 360 s-1 for PTOV1A and 380 s-1for Med25 AcID (Fig 2.11a-e). The 
fast on rate is most likely the result of enhanced electrostatic interactions.  
Figure 2.10: The binding faces of AcID. A) The H1 binding site is formed by β1-β3-β5 and α2 (shown in teal). 
Activators  such as ERM and one of the TADs of VP16 bind to this site.14,15 B) The H2 binding site is formed by β6-
β7-β4 and α1 (shown in red). ATF6α and the other VP16 TAD bind to this face.11,14 
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Only one conformation state is observed, with 100% population state observed after 
binding. This is quite different from Med25 AcID, which has three very clear conformational 
changes.  While it is highly likely that PTOV1A is undergoing additionally conformational states, 
the low energy differences between the different conformers is masking the identifiable changes 
between states. This is consistent with the observation that PTOV1A is more unstructured.  
 
Figure 2.11: Experiments used to define PTOV1A•ERM binding parameters. A) The H1 binding face of Med25 
AcID. In green are the key perturbed residues that are conserved in PTOV1A, and in red are the differences, such as 
K411R, K440E and Y486, which is a Cys in PTOV1A 15,21 B) Plotted association traces of PTOV1A•ERM. 
C)Representative association trace of 350 nM PTOV1A and 250 nM ERM, fit to a single exponential. D) Plotted kobs 
to determine kon. D) Dissociation trace of PTOV1A•4-DMN-ERM. 2 µM PTOV1A was precomplexed with 0.5 µM 
DMN-labeled ERM, and then rapidly mixed with 25 µM unlabeled ERM. The trace was fit to a single exponential. 
For reference, Med25 AcID•ERM associationa and dissociation traces were both fit to triple exponentials.11  
 
Binding at the H2 face suggests stabilization of energetically favorable conformer upon binding  
The transcriptional activator ATF6α, responsible for initiating the unfolded protein 





Koff =360±10s-1   
C. 
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that of ERM (Fig. 2.10).9,11 Key residues R466 and M523, located on α2 and β7 respectively, were 
shown to undergo significant chemical shift perturbations in HSQC NMR experiments, and 
mutations to these residues disrupted ATF6α binding.  Both residues are conserved in PTOV1A, 
with neighboring residues. However, given the proposed increase in malleability due to the loss of 
structure, we propose there will be a loss in observed conformational states (Fig. 2.12a).  
 PTOV1A had a kon half that of Med25 AcID when bound to ATF6α, 310 µM-1s-1 and 610 
µM-1s-1 respectively. Additionally, the dissociation rate constant was 2-fold slower, 140 s-1 for 
Med25 and 49 s-1 for PTOV1A, leading to a similar Kd for both Med25 and PTOV1A (Fig. 2.12). 
Med25 AcID underwent three distinct conformational changes, with the first conformation state 
being consisting of the highest population (>80%). Only one conformation state was detected for 
PTOV1A in the stopped flow kinetics experiments. However, this may be due to the other 
populations being too small to detect with current methods, or that the timescale of exchange was 
too fast to observe. This is likely due to the loss in secondary structure, as described above.  
      
Figure 2.12: Experiments used to define PTOV1A•ATF6α binding parameters. A) The H2 binding face of Med25 
AcID. In green are the key perturbed residues that are conserved in PTOV1A, and in red is Y486, which is a Cys in 






Koff =49±2s-1   
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PTOV1A and 125 nM ATF6α, fit to a single exponential. D) Plotted kobs to determine kon. D) Dissociation trace of 
PTOV1A•4-DMN- ATF6α. 1 µM PTOV1A was precomplexed with 0.25 µM DMN-labeled ATF6α, and then rapidly 
mixed with 25 µM unlabeled ATF6α. The trace was fit to a single exponential. For reference, Med25 AcID• ATF6α 
assciation and dissociation traces were both fit to triple exponentials.11  
 
A TAD that binds to both faces reveals complex conformational changes   
The two amino-terminal TADs of VP16, termed H1 and H2, bind to both faces of VP16, 
overlapping with the binding regions of ERM and ATF6α.8,14 NMR titration experiments revealed 
that the H1 TAD of VP16 binds to a groove in Med25 formed by β1-β3-β5 and α2 on the H1 
binding face. The H2 TAD was found to bind to a groove on the opposite H2 binding face formed 
by β6-β7-β4 and α1 (Fig. 2.10).14 It is hypothesized that the loss in structural order of PTOV1A 
compared to Med25 AcID, in addition to VP16 binding to both faces over a greater area, will result 
in significant changes in rate constants.  
Unlike Med25 AcID, PTOV1A complexed with VP16 was shown to undergo additional 
kinetic phases.  An ‘inverted experiment’ was used to the support the mechanism of 
conformational changes after binding to Med25 AcID. Additionally, global fitting was completed 
using the calculated rate constants from the standard experiments in order to further validate the 
model. Figure 2.13 illustrates the results of PTOV1A association and dissociation complex 
formation with VP16. PTOV1A’s kon was approximately half that of Med25, 1,100 µM-1s-1 for 
Med25 and 650 µM-1s-1 for PTOV1A. Interestingly, PTOV1A•VP16 had a Kd that was 4.6-fold 
tighter than Med25 AcID.  
The PTOV1A and Med25 were shown to undergo two conformational changes. The fast 
phase is linearly dependent upon protein concentration. However, due to the amplitudes of change 
being too small to accurately derive rate parameters, we were unable to calculate population 
distributions. Interestingly, these data suggest that the PTOV1A•VP16 system is the most similar 
to that of Med25 AcID in terms of conformational ensembles. Despite a slower kon, we observed a 








koff slower for PTOV1A than Med25 AcID, 7.1 s-1 versus 102 s-1, leading to a significantly tighter 
Kd.  Moreover, there is a +2 charge difference between PTOV1A (+9) and Med25 AcID (+7), 
which is likely resulting in the slower association rate given the critical role of electrostatics.  
 
Figure 2.13: Experiments used to define PTOV1A•VP16 binding parameters. A) Plotted association traces of 
PTOV1A• VP16. B) Representative association trace of 100nM PTOV1A and 100 nM VP16, fit to a double 
exponential. C) Plotted kobs to determine kon. D) Dissociation trace of PTOV1A•4-DMN- ATF6α. 250 nM PTOV1A 
was precomplexed with 100 nM DMN-labeled VP16, and then rapidly mixed with 15 µM unlabeled VP16. The trace 
was fit to a single exponential. For reference, Med25 AcID• VP16 association and dissociation traces were both fit to 
double exponentials.  
 
Complex formation with helical coactivators and activators typically proceeds by fast 
association and dissociation rate constants. Previous work by Dr. Matt Henley and the Mapp lab 
demonstrates that Med25 AcID forms complexes consistent with this observation. Med25 AcID 
had kon values that were 1-2 orders of magnitude faster than previously observed with most other 
activator•coactivator systems, likely due to the role of electrostatics (Fig. 2.8).   PTOV1A complex 
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formation demonstrated similar trends, with noticeable differences in complex dissociation, often 
forming tighter complexes. While Med25 AcID complexes showed kon values ranging from 300 to 
1,100µM-1s-1, and koff values between 100 and 400s-1, PTOV1A complex formation was often 
slower than Med25, but had koff and KD values that were for some interactions, over 4-fold tighter 
than that of Med25 AcID. Taken together, these data suggest that while PTOV1A does not 
demonstrate significantly different binding mechanisms, the changes in sequence alter the 
conformational ensembles observed. This is likely due to the loss in structure and thermal stability, 
which in turn can lower the energy differences between conformation states and thus masking 
changes between conformation states.  
Table 2.2: Calculated rate constants for PTOV1A and Med25 AcID. Values were measured using transient 
stopped flow kinetics, and are the average of 2-3 traces. Reported error is SDOM.  
 
Activators PTOV1A kon (µM-1s-1) PTOV1A koff (s-1) Med25 kon (µM-1s-1) Med25 koff (s-1) 
ERM 780 ± 100 360 ± 10 ~300 380 ± 40 
ATF6α 310 ± 100 49 ± 2 610 ± 40 140 ± 7 
VP16 650 ± 90 7 ± 1 1,100 ± 100 102 ± 6 
 
2.4 Conclusions and Assessment  
Coactivators must be able to quickly bind transcriptional activators in a specific manner to 
initiate transcription. Adding to the complexity of seemingly featureless binding interfaces, 
coactivators must be able to bind a multitude of binding partners, each with a different outcome.  
These ‘fuzzy interactions’ have long been termed undruggable due to the evasive nature of their   
While it was originally proposed that binding was driven through electrostatic and hydrophobic 
interactions, this model does not account for the intricate specificity and selectivity required for 
such a highly regulated process as transcription initiation. Towards this end, recent work in the 
Mapp lab has demonstrated that molecular recognition is driven through conformational changes 
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driven through dynamic regions.  In some cases, such as that observed with CBP GACKIX, upon 
activator binding to the ABD, there is a winnowing of conformers, allowing a unique state specific 
to each interaction.10,25    
Using AcID paralogs, we set out to determine how sequence deviations in the dynamic 
substructures affected binding mechanisms. In this chapter we demonstrate that there is a predicted 
loss in structure for the AcID motifs. The guiding hypothesis was that the sequences differences 
would influence binding selectivity and also the conformational changes of the resulting 
complexes. Using equilibrium binding experiments, we observed that there were only modest 
changes in binding affinity. Transient stopped-flow kinetics provided insight into the binding 
mechanisms of PTOV1A and Med25 AcID. We observe that while there is not a significant change 
in mechanism, the sequence deviations result in change of conformational plasticity. This is 
directly observed by PTOV1A undergoing less conformation transitions upon activator binding. 
While there are most likely some conformation states that cannot be detected by current available 
methods, it suggests that there is a differential response upon binding to PTOV1A, thus indicating 
that these changes in secondary structure alter the binding modes for AcID•activator interactions. 
Taken together, the work in this chapter demonstrates that sequences changes in the 
dynamic substructures alter the conformations. Given that PTOV1 has been observed to 
outcompete Med25 for binding to CBP when overexpressed in metastatic prostate cancer, these 
changes in sequence are highly implicated in function.  Specifically, the changes in conformational 
plasticity as a result of the sequence deviations may alter transcriptional output by altering the 
AcID•activator complex formation timescale. Due to its large role in many cancer states, it would 
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be critical moving forward to determine PTOV1’s role in modulating transcription, as well as 
further dissect its antagonistic behavior against Med25.  
Figure 2.14: Plotted kobs of PTOV1B•ERM. Above is the plotted, fast linear phase PTOV1B associating to ERM. 
ERM was fit to a double exponential, compared to Med25 AcID, which was fit to a triple exponential.   
 
Moving forward, it would be critical to study how other AcID motifs are implicated in 
binding. For example, association experiments were conducted with PTOV1B•ERM, we see a kon 
almost identical to that of Med25 AcID (~300 µM-1s-1) (Fig. 2.14). PTOV1B exhibited two 
conformational changes, while PTOV1A exhibited one and Med25 AcID exhibited three. What is 
even more interesting is that PTOV1B has higher sequence deviation to Med25 as well, with an 
overall increase in hydrophobic residues, but a loss in negative residues (Fig. 2.2). It is therefore 
critical to continue to study PTOV1B, as this can help elucidate the paradigm of how sequence 
deviations in dynamic regions can alter binding mechanisms.  
Additionally, we can expand our understanding of molecular recognition within AcID 
motifs by studying an AcID motif that has equal sequence deviations in both the barrel and helical 
regions. Med25 AcID has only been identified in metazoans, including Arabidopsis thaliana, a 
model plant organism.26 Similar to human Med25, plant Med25 was found to associate to the 
Mediator complex (Fig. 2.15).26,27   Despite the general structure being conserved, plant Med25 
AcID only shares 16% sequence identity, with sequence deviations spread equally across the β-
barrel and dynamic substructures.  Interestingly, there appears to be a loss in one of the helices. 
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Experiments to determine the apparent Kd at equilibrium show that Med25’s cognate binding 
partners bind to plant Med25 with similar affinity (Table 2.3). Further biophysical studies using 
the plant Med25 AcID motif coupled with the PTOV1 AcIDs can help elucidate how structural 
features play a role in dictating molecular recognition.  
Figure 2.15: Predicted structure of Arabidopsis thaliana’s Med25 AcID. Sharing only 16% sequence identity, plant 
Med25 AcID is an excellent addition to help elucidate the binding mechanisms of coactivators.  There is a loss 
predicted loss in secondary structure, specifically with the loss in the top helix, α2. 
 
 
Table 2.3: Apparent Kd’s of  the four AcID motifs. Despite only sharing 16% sequence identity, plant Med25 AcID 
is capable of recognizing Med25 AcID’s binding partners with similar affinity. Data is in triplicate and the error is 
reported as SDOM.   
 
 
 PLANT MED25 MED25 PTOV1A PTOV1B 
ATF6Α 0.16 ± 0.2 µM 0.52 ± 0.6 µM 0.20 ± 0.01µM 1.2 ± 0.2 µM 
ERM 0.59 ± 0.02 µM 0.59 ± 0.02 µM 0.42 ± 0.04 µM 0.24 ± 0.03 µM 
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2.5. Materials and Methods   
Plasmids for protein expression  
 Prof. Patrick Cramer generously provided the Med25 expression plasmid pET21b-Med25 
(394-543)-His6. Plasmid sequence identity was confirmed via standard Sanger sequencing 
methods on an Applied Biosystems 3730xl DNA Analyzer at the University of Michigan DNA 
Sequencing Core and analyzed using SeqMan Pro from the Lasergene DNASTAR software suite.  
 pET21b plamids for PTOV1A (88-235) and PTOV1B (253-398) were purchased from 
Genescript. Both plasmids contain a C-terminal 6x His tag. Plasmid sequence identity was 
confirmed via standard Sanger Sequencing as described above.  
 Plant Med25 AcID was designed using IDT gene designer and placed in a pmcsg7 
expression vector.  
Expression of Med25 AcID and plant Med25 AcID  
Med25 AcID and was expressed as follows. Plasmids were transformed into chemically 
competent Bl21-AI cells (Novagen), plated onto LB/ampicillin/streptomycin agar, and incubated 
at 37˚C overnight. The next day, plates were stored at 4˚C until further use. In the evening, a single 
colony from the plate was selected and placed in 50 mL of Terrific Broth (TB) with 0.1 mg/mL 
ampicillin and 0.05 mg/mL streptomycin and incubated at 37˚C at 250 RPM. The following 
morning, 5 mLs from the starter culture was added to 1L TB with 0.1 mg/mL ampicillin and 0.05 
mg/mL streptomycin and was grown to an OD600 of 0.6-0.8 at 37˚C, 250 RPM. Once OD600 was 
reached, temperature was reduced to 20˚C for a minimum of thirty minutes before induction. Cells 
were induced with 0.250 mM IPTG and 2% arabinose. Bacteria were shaken overnight at 20˚C, 
250 RPM. The next morning, cultures were centrifuged at 7000 x g for 20 minutes at 10˚C. Cell 
pellets were stored at -80˚C until purification.  
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Expression of PTOV1A and PTOV1B 
 pET21b-PTOV1A(88-235)-His6 and pET21b-PTOV1B(253-398)-His6 were both 
expressed using the same method. Plasmid was transformed into chemically competent Bl21-AI 
cells, plated onto LB/ampicillin/streptomycin agar and incubated overnight at 37˚C. The next day, 
plates were stored at 4˚C until needed. In the evening, a single colony was selected and added to 
50 mL of TB with 0.1 mg/mL ampicillin and 0.05 mg/mL streptomycin and incubated overnight 
at 37˚C, 250 RPM. The following morning, 7 mLs from the starter were added to 1 L TB with the 
same concentrations of antibiotics used for the overnight and grown to an OD600 of 1.0 at 37˚C, 
250 RPM. Once OD600 was reached, the temperature was reduced to 30˚C for at least 30 min before 
induction. Cells were induced with 0.300 mM IPTG and 2% arabinose. Bacteria were shaken 
overnight at 30˚C, 250 RPM. The next morning, cultures were centrifuged at 7000 x g for 20 
minutes at 10˚C. Cell pellets were stored at -80˚C until purification.   
Purification of expressed proteins.   
 All proteins were purified using the same FPLC purification methods and were subjected 
to affinity and ion exchange chromatography. Frozen cell pellets were thawed and resuspended in 
lysis buffer (50 mM phosphate, 300 mM NaCl, 10 mM imidazole, pH 6.8, 0.7 µL/mL β-ΜΕ, 1 
protease inhibitor tablet) and lysed via sonication. Cellular debris was pelleted by centrifugation 
for 20 min at 9500 RPM. The clear cell lysate was then subjected to one more round of sonication 
to help breakup DNA, and then centrifuged again. Supernatant was filtered using 0.45 µM syringe 
filter (CellTreat) and loaded directly onto an AKTA Pure FPLC with a 5 mL Ni-NTA column 
(HisTrap HP, GE Healthcare) using a gradient of 100% Buffer A (50 mM sodium phosphate, 300 
mM NaCl, and 30 mM imidazole, pH 6.8) to 100% Buffer B (50 mM sodium phosphate, 300 mM 
NaCl, and 500 mM imidazole, pH 6.8) over ten column volumes. AcID-containing fractions were 
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polled and underwent a second purification via cation exchange (HiTrap SP HP, GE Healthcare) 
with a gradient of 100% Buffer A (50 mM sodium phosphate, 1mM DTT, pH 6.8) to 100% Buffer 
B (50 mM sodium phosphate, 1 M NaCl 1mM DTT, pH 6.8) over fifteen column volumes. 
Fractions containing purified protein were pooled and dialyzed into storage buffer (10 mM sodium 
phosphate, 100 mM NaCl, 0.001% NP-40, 1% glycerol, 1mM DTT, pH6.8). Following dialysis, 
protein concentration was determined via UV/Vis spectroscopy on a NanoDrop at 280 nm using 
an extinction coefficient, ε=22,460 M-1cm-1. Protein identity was confirmed via mass spectrometry 
(Agilent QToF) and purity was assed via SDS-PAGE on a 4-12% bis-tris gel stained using Quick 
Coomassie (Anatrace). Purified protein was aliquoted, snap frozen, and stored at -80˚C.  
Direct binding experiments  
 Direct binding experiments measured by fluorescence polarization were performed in 
triplicate. Final sample volume was 20 µL in a low volume, round bottom, non-stick, 384-black 
well plate (Corning). FITC labeled peptides were diluted in binding buffer (5 mM sodium 
phosphate, 100 mM NaCl, 10% glycerol, 0.001% NP-40, pH 6.8) to 40 nM. 10 µL Protein was 
serially diluted two-fold with assay buffer going down the plate, allowing for eight total 
concentration readings per experiment. The final well was a negative control, peptide only. 10 µL 
of diluted peptide was then added to each well for a final concentration of 20 nM. The plate was 
then incubated for 30 min at room temperate before fluorescence polarization was read on  
PHERAstar plate reader (polarized excitation at 485 nM and emission intensity measured through 
a parallel and perpendiculary polarized 535 nM filter. 
 GraphPad Prism was used to calculate the apparent KD and indicated error (SDOM) via the 
equation below. A binding isotherm that accounts for ligand depletion, assuming a 1:1 binding 
model), was fit to the observed values as a function of protein in order to obtain the apparent 
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equilibrium constant, where ‘a’ and ‘x’ are the total concentrations of fluorescent peptide and 
protein, respectively. ‘b’ is the maximum observed polarization value, and ‘c’ is the minimum 
value.  
𝑦 = 𝑐 + (𝑏 − 𝑐) ×






Transient kinetic experiments  
 Stopped-flow kinetic assays were performed on a Kintek SF-2001 stopped-flow equipped 
with a 100 W xenon arc lamp in two syringe mode. The 4-DMN fluorophore was excited at 440 
nm and its emission was monitored at wavelengths greater than 510 nm, using a long-pass filter 
(Corion). All experiments were run at 10˚C in buffer (10 mM sodium phosphate, 100 mM NaCl, 
1% glycerol, 0.001% NP-40, pH 6.8), and solutions were allowed to equilibrate on the instrument 
for at least five minutes before the experiment was run. Concentrations reported are after rapid 
mixing. All kinetic traces are an average of 20-80 individual traces, and in triplicate. A series of 
exponential equations were fit to the transient kinetic time courses, F(t) as described in the below 
equation, to obtain fluorescence amplitude (Fn) and the observed rate constants (kobs) for each 
exponential phase, where F(0) is the initial fluorescence intensity and t=time.  
𝐹(𝑡) = 𝐹(0) + 𝛴𝐹#	 ×	(1 − 𝑒%&!"#,#×)) 
 Association experiments were performed by mixing excess protein with a constant 
concentration of labeled activator. Dissociation experiments were performed by precomplexing 
protein with labeled activator and mixing with excess of the corresponding unlabeled activator. 
The concentrations of the association experiments are as follows: 50 nM VP16, 125 nM ATF6α, 
and 250 nM ERM. The concentrations for the dissociation experiments are as follows: 50 nM 
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labeled VP16, 100 nM protein, 10 µM unlabeled VP16; 250 nM labeled ATF6α, 500 nM protein, 
10 µM unlabeled ATF6α; 500 nM labeled ERM, 1µM protein, 50 µM unlabeled ERM. The labeled 
activator concentrations in both association and dissociation experiments were chosen to maximize 
S/N and minimize ligand depletion effects in the association experiments. The plotted kobs is the 
rate parameter from the fast phase from the first amplitude in the association experiments and fit 
to a linear equation using Kaleidagraph.  
𝑘*+, = 𝑘*#	𝑥	[𝑃𝑟𝑜𝑡𝑖𝑒𝑛] + 𝑘*-- 
Solid-phase peptide synthesis and purification 
Table 2.4 Sequence of peptides used in this study  
Entry  Peptide Sequence  
1 VP16(438-490) AcALDDFDLDMLGDGDSPGPGFTPHDSAPYGALDMADFEFEQMFTDALGI 
DEYGG 
2 ATF6α(38-75) AcFTDTDELQLEAANETYENNFDNLDFDLDLMPWESDIWD 
3 ΕRM(38-68) AcDLAHDSEELFQDLSQLQEAWLAEAQVPDDEQ 





























4-DMN- βAla- LPPLDSEDLFQDLSHFQETWLAEAQVPDSDEQ 
 
 The peptides listed in Table 2.3 were made using standard FMOC solid-phase synthesis 
methods on a Liberty Blue Microwave Synthesizer (CEM). Deprotection of the FMOC groups 
were done in 20% piperidine (ChemImpex) in DMF that was sumplemented with 0.2 M Oxyma 
Pure (CEM) and irradiating under variable power to maintain a temperature of 90˚C for one minute. 
For coupling reactions, 5 eq of amino acids relative to resin (CEM, ChemImpex, and 
NovaBiochem) were added to diisopropylcarbodiimide  (7 eq, ChemImpex) and Oxyma Pure (5 
eq) in DMF and irradiated at variable power to maintain a temperature of 90˚C for 4 minutes. 
Between all couplings and deprotections, the resin was rinsed four times with excess DMF.  
 Following synthesis, peptides 1-4 were deprotected one final time and acetylated at the 
amino terminus using a cocktail of acetic anhydride and triethylamine (Fisher Scientific) in 
dichloromethane. Peptides 5-8 were deprotected one final time following synthesis, and then 
treated with fluorescein isothiocyanate (FITC, ThermoFisher) in the presence of N,N-
diisopropylethylamine (Sigma Aldrich). The remaining peptides were deprotected and then 
subjected to one final coupling N-terminally to 4-DMN linked to a β-alanine prior to cleavage. All 
peptides were cleaved in 95% trifluoroacetic acid (Sigma Aldrich), 2.5% H20 and 2.5% 
triisopropylsilane (Sigma Aldrich) for four hours, then filtered. The remaining solution was 
concentrated under nitrogen and precipitated in cold diethyl ether.  
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 The precipitated peptide was dissolved in 50/50 0.1% TFA in water and acetonitrile with 
minimal ammonium hydroxide to help with solubility, syringe filtered using a 0.45µn, and purified 
via HPLC purification. The peptide was purified using reversed phase HPLC on an Agilent 1260 
Series instrument with a 250 x 10 mm Luna Omega 5 µm PS C18 column (Phenomenex) using a 
gradient elution of acetonitrile in 0.1% TFA in water. Purified peptide were tested for purity using 
analytical HPLC, and identity was determined via mass spectrometry under negative ion mode 
(Agilent ToF). Once determined to be pure, peptides were dissolved in minimal DMSO and 
quantified via UV/Vis spectroscopy using either Tyr absorbance at 280 for acetylated peptides 
(ε280=1,280M-1cm-1), FITC absorbance at 495 nm (ε495=72,000 M-1cm-1), or 4-DMN absorbance 
at 440 nm (ε440=10,800 M-1cm-1).  
Circular dichroism of proteins  
 Circular dichroism spectra of Med25, PTOV1A/B and plant Med25 AcID were obtained 
using a J-715 spectropolarimeter (Jasco Inc) using a 1 mM quartz cuvette. Protein was dialyzed 
into CD buffer (5 mM sodium phosphate, 100 mM NaF, pH 6.8) to remove any trace of NaCl. 
Final protein concentrations of 25 µM were used. A background scan was performed using buffer 
only. Data was collected from 260-180 nm in 1 nm increments at a scanning speed of 100 nm/min. 
Background subtracted data was converted to mean residue ellipticity using the equation below. Ψ 
is the CD signal in degrees, n is the number of amides, l is the pathlength in centimeters, and c is 
the concentration in decimoles/cm3. Each spectra reported is the average of eight scans.  
[𝛩] = Ψ/(1000 × n × l × c) 
Circular dichroism for observed thermal melts 
 Following the collection of CD spectra, CD-observed thermal melts were conducted using 
the ‘variable temperature’ module (see above for instrument, buffer, concentrations, etc. Protein 
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was heated from 20-100˚C at 1˚C/min, and monitoring the molar ellipticity at 208 nm and 222 nm. 
Data was collected at every degree point. The molar ellipticity values were then converted to 
‘fraction unfolded’ and the Tm was determined by fitting the data to Prism’s ‘log(inhibitor) vs 
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The activation of gene transcription in eukaryotic organisms is regulated by the formation 
of protein-protein interactions.  These interactions are between DNA-bound transcription factors 
and coactivators. These coactivators act as central hubs, binding to a multitude of different binding 
partners, and their activator binding domains (ABDs) are the molecular recognition units. ABDs 
contain dynamic substructures, loops and helices, that offer a high degree of malleability. These 
dynamic substructures allow for allosteric communication within the ABDs. In this chapter, we 
use coactivator paralogs, termed AcID, that deviate in the sequences of their dynamic substructures 
to determine how these changes alter allostery. Using a biophysical approach, we demonstrate that 
the two binding faces of AcID are in allosteric communications. Moreover, nature of allostery is 
different among the paralogs. We use this information to test how an identified allosteric modulator 
alters binding amongst the AcID motifs, demonstrating that changes in the dynamic regions alter 
binding. Lastly, using transient stopped-flow kinetics, we show how a family of transcriptional 
activators, containing minor deviations in sequence, can induce different conformations amongst 
the AcID paralogs. Taken together, the work in this chapter demonstrates the importance of 
dynamic substructures in coactivators, with even minor deviations in sequence resulting in changes 
to allostery and binding modes.  
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3.2 Introduction  
 
Protein-protein interactions (PPIs) between activators and coactivators are critical for gene 
regulation.1,2 Despite their critical role, the mechanism by which binding occurs remains poorly 
understood. Early biochemical and biophysical studies suggested that molecular recognition was 
largely nonspecific, occurring through hydrophobic and electrostatic interactions.3  However, as 
outlined in Chapter two, recent work in the Mapp lab has demonstrated that this nonspecific view 
of recognition is incomplete, and that specific interactions between dynamic substructures in 
coactivators and activators underpins complex formation.4,5 Another role of the dynamic 
substructures is in allosteric communication between binding sites of coactivators.4  
Often, ABDs are comprised of helices connected by dynamic loops.11 The ABD of the 
Mediator complex subunit Med25, termed Activator Interaction Domain (AcID) is structurally 
unique in that it contains a seven stranded β-barrel, flanked by helix and loop domains. While it 
was originally proposed that the barrel region is critical for molecular recognition, recent work in 
the Mapp lab indicates that the dynamic loops and helices undergo significant conformational 
changes upon binding (Fig. 3.1) Further, these dynamic regions can help regulate cooperativity 
and selectivity in binding.6–9  
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Figure 3.1: Putty figure of Med25 AcID illustrates dynamic substructures. Above is depiction showing the 
emerging model for AcID-activator complex formation. Using the NMR coordinates for Med25 AcID (PDB ID code 
2xnf), the initial structure of  Med25 was built in CHARMM using the Multiscale Modeling Tools for Structural 
Biology (shown in A). B) VP16 (438-454)G450C, a peptide tethered to Med25 AcID via C506, was constructed in 
CHARMM as a helical peptide. This was then patched in CHARMM to Med25 through the formation of a disulfide 
bond at C506 (shown as a transparent blue helix). Coloring correlates to the degree of dynamical behavior, with the 
highest degree observed in the loops and helices.4 Data and figure were generated by Amanda Peiffer. 
 
In the previous chapter, I demonstrated that the sequence differences in the dynamic 
regions of AcID paralogs correlated with changes in affinity for activators and significant 
differences in conformational dynamics of the complexes. Taken together, these data support a 
role in for the dynamic substructures in molecular recognition. Here we use the AcID paralogs to 
determine how sequence difference in the dynamic regions will alter allosteric communication 
(Fig. 3.2). We establish that allosteric communication is conserved in the AcID motifs. Using this 
information, we look at how changes in the dynamic substructures alter allosteric modulator 
binding. Additionally, using a biophysical approach, we examine how slight changes in TAD 
sequence can result in differential changes in coactivator conformations. Taken together, these 
data demonstrate that sequence changes in the dynamic regions are highly implicated in allosteric 
communication.  
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Figure 3.2: Sequence alignment of the AcID paralogs.  Shown in yellow are the sequences differences. Boxed are 
the dynamic substructure regions.  Sequence alignments of the AcID homologs reveals that PTOV1A shares 81% 
sequence identity to Med25 AcID, and PTOV1B shares 71% identity. Specifically, while there are some deviations, 
the b-barrel remains largely conserved. In contrast, residue deviations, such as charge flips and loss of charges, are 
found in the dynamic loop and helical regions.  
 
3.3 Results and Discussion  
3.3.1 PTOV1A’s binding faces are in allosteric communication  
Figure 3.3: The two binding faces of AcID.  AcID contains two binding faces termed H1 and H2, named for the 
two TAD domains of VP16.10 For reference, ETV5/ERM binds to the H1 face, and ATF6α binds to the H2 face.4,11  
 
Through NMR studies and mutational analysis, it has been demonstrated that Med25 AcID 
contains two distinct binding faces, termed H1 and H2 (Fig. 3.3).4,12,13 This raised the question if 
these two faces were in allosteric communication. By measuring the dissociation rate constants of 
Med25 AcID with various combinations of H1 and H2 binding face partners, Dr. Matthew Henley 
was able to demonstrate that the two faces of Med25 AcID are indeed in allosteric communication. 
Fluorescently labeled probes that would interact with the H2 binding face, ATF6α (38-75) and 
VP16 (467-488), were used to asses changes in the dissociation rate constant upon ternary complex 
Loop 1 Loop 2 
Helix 1 Helix 2 Loop 3 
Loop 4 Helix 3
Med25_AcID       --SVSNKLLAWSGVLEWQEKPKPASVDANTKLTRSLPCQVYVNHGENLKTEQWPQKL-IM
PTOV1A           ---LSNKLLAWSGVLEWQEKRRPYS-DSTAKLKRTLPCQAYVNQGENLETDQWPQKL-IM
PTOV1B           VQIVNNKFLAWSGVMEWQE-PRP---EPNSRSKRWLPSHVYVNQGEILRTEQWPRKL-YM
                     
Med25_AcID       QLIPQQLLTTLGPLFRNSRMVQFHFTNKDLESLKGLYRIMGNGFAGCVHFPHTAPCEVRV
PTOV1A           QLIPQQLLTTLGPLFRNSQLAQFHFTNRDCDSLKGLCRIMGNGFAGCMLFPHISPCEVRV
PTOV1B           QLIPQQLLTTLVPLFRNSRLVQFHFT-KDLETLKSLCRIMDNGFAGCVHFSYKASCEIRV
               
Med25_AcID       LMLLYSSKKKIFMGLI-PYDQSGFVNGIRQVITN--
PTOV1A           LMLLYSSKKKIFMGLI-PYDQSGFVSAIRQVITTRK
PTOV1B           LMLLYSSEKKIFIGLI-PHDQGNFVNGIRRVIA---
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formation when the H1 face became occupied. When ERM was bound to the H1 site, VP16 had a 
20% reduction in koff, while ATF6α had a 25% reduction (Fig. 3.5).4  
 
Figure 3.4: Chemical shift perturbations induced by VP16. Mapped onto Med25 AcID in (PDB 2xnf) are the 
chemical shift perturbations induced by VP16 are shown in blue. In black are the residues that displayed significant 
line broadening or were unassignable due to large shifts. As depicted, many of these perturbations are found on 
dynamic substructure Experiments and assignments were completed by Dr. Andrew Henderson and Dr. Brian 
Linhares.4 Circled in red are the loop regions that undergo significant perturbations upon VP16 binding. Another view 
of the loops are shown on the right. In blue is loop 2 and in green is loop 3.  
 
  We next wanted to determine if this internal allosteric network extended to PTOV1A. The 
bottom loop regions, loops 2 and 3 show significant peturbations in Med25 AcID (Fig. 3.4). In 
PTOV1A, these regions in have quite a bit of sequence deviation. Specifically, the charge in loop 
2 has an overall negative charge compared to the same loop in Med25 AcID, which has an overall 
positive. (Fig. 3.4).  These bottom loops have been shown to be critical for allostery in Med25 
AcID, and even the use of a covalent chaperone tethered to loop 3 has successfully recapitulatd 
allosteric changes.4 We therefore hypothesize that these sequence deviations will alter the 
allosteric network in PTOV1A, directly measurable by monitoring the koff.14  
  To test this hypothesis, a similar experiment was set up with PTOV1A. PTOV1A’s binding 
faces were 100% occupied by precomplexing with DMN-labeled ATF6α, an H2 binder, and 
unlabeled ERM, an H1 binder, and unlabeled ATF6α served as the competitor. We monitored 
changes to the H2 face through changes in koff. When the H1 site is occupied, we observe an 18% 
increase in koff of the H2 face, an opposite trend to what we observe for Med25 AcID in the same 
Loop 3 
Loop 2 
Loop 3 Loop 2 
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experiment (Fig. 3.5).  This suggests that the lifetime of the ternary complex for PTOV1A is 
shorter than the lifetime of the binary complex with ATF6α, an unusual trend for coactivators. 
These data support that PTOV1A binding faces are in allosteric communication. Given the overall 
lack of structure, as described in Chapter two, this reduction in binding is likely facilitated by the 
increase in dynamic loops of PTOV1A.  By demonstrating that PTOV1A’s two binding faces are 
in allosteric communication, we can theoretically modulate binding by targeting one of these 
dynamic regions.   
 
Figure 3.5: Kinetic experiments show allosteric within AcID. A) Schematic of the experiment. B) Comparison of 
koff for VP16 (H2) (blue bars) for Med25 AcID, Med25 AcID with VP16 (H1)G450C covalently tethered, and Med25 
AcID with ERM prebound; the red bars summarize data from an analogous experiments with ATF6α. C) Dissociation 
experiment of (left), and the allosteric complex (right). 250 nM protein was prebound to 125 nM DMN labeled ATF6α 
A.  B.  
C.  PTOV1A-ATF6α Dissociation PTOV1A-ERM-ATF6α Dissociation  
koff=49 ± 2 s-1  koff=58 ± 4 s-1  
 57 
and 7.5 µM unlabeled ERM. The complex was then rapidly mixed with unlabeled ATF6α. Both traces were fit to 
single exponentials. koff values are the average from three traces and the reported error is the SDOM.15  
 
3.3.2 A natural product allosterically inhibits AcID interactions 
 The xanthone natural product garcinolic acid (GA) was identified in natural product screen 
conducted by Dr. Julie Garlick as an inhibitor of Med25 AcID. With an IC50 of 9.1 µM against 
ERM, GA with modest potency (Fig. 3.6). In order to determine where GA was binding to binding 
to Med25 AcID, HSQC NMR experiments led by Dr. Matthew Beyersdorf were conducted (Fig. 
3.7). Interestingly, GA was shown to bind to the H2 face of Med25 AcID, suggesting that GA is 
an allosteric inhibitor of the Med25 AcID•ERM interaction.   
 
Figure 3.6: Garcinolic acid is a natural product that inhibits TAD binding to coactivators A) Structure of 
garcinolic acid, a xanthone natural product identified in a library screen. B) FP based competition assays of GA with 
CBP  GACKIX•MLL (see Appendix 1 for more information) and Med25•ERM. Protein was incubated with 20 nM 
final FITC-labeled peptide at 50% occupancy. The max concentration of GA was 200 µM. C) FP based competition 
assays of GA with PTOV1A•ERM. Protein was incubated with 20 nM final FITC-labeled peptide at 50% occupancy. 
The max concentration of GA was 200 µM. D) he H1 binding face of Med25 AcID. In green are the key perturbed 
residues that are conserved in PTOV1A, and in red are the differences, such as K411R, K440E and , which is a Cys 
in PTOV1A 11,12 
 

















) IC50= 5.6± 0.4µM 
IC50= 9.1± 2µM 
















) IC50= 1.9 ± 0.3 µM 
PTOV1A 
log [GA] (µM) 
A. B.  
C.  D.  
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 Having shown that PTOV1A’s two binding faces are in allosteric communication, we 
wanted to determine how an allosteric modulator such as GA would affect TAD binding. We 
hypothesized that due to the changes in the allosteric network, this would be reflected by an 
allosteric modulator. Using a fluorescence polarization-based competition assay, we measured the 
IC50 value starting with a maximum concentration of 200 µM GA, we titrated in decreasing 
concentrations of GA.  PTOV1A was precomplexed with FITC-labeled ERM at 50% occupancy. 
We show that GA has an IC50 of 1.9 µM against ERM, exhibiting a six-fold tighter inhibition than 
Med25 (Fig. 3.6). This is likely due to a loss in surrounding electrostatics on PTOV1A in the 
proposed ERM binding site coupled with the changes to the bottom loops in PTOV1A. Taken 
together, these data support overarching hypothesis that changes in the sequences of the dynamic 
substructures alters binding of an allosteric modulator.  
Figure 3.7: NMR experiments show the binding site of GA. Using 1H-15N HSQC NMR experiments, GA caused 
the biggest perturbations on the H2 face. Increasing shades of red indicate more chemical shift perturbations, with the 
red balls depicting residues that underwent complete peak broadening. Data and figures made by Dr. Matthew 
Beyersdorf.  
 
3.3.3 AcID motifs can discern even small changes in sequence identity   
Figure 3.8: Sequence alignment of the ETV/PEA3 TADs. The middle portion of the TAD sequence has been 
predicted to have an increased propensity to take on a helical structure, as depicted. The four N-terminal residues are 
more likely to be disordered.  
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Recent work in the Mapp lab by Dr. Matthew Henley demonstrated surprising specificity 
of TAD recognition using the ETV/PEA3 family of ETS transcriptional activators, including 
ETV1, ETV4 and ETV5/ERM (Fig. 3.8).11,16,17 The ETV•Med25 AcID interactions appeared to 
behave as a prototypical TAD•ABD interaction, occurring over a shallow binding surface and 
drive by hydrophobic and electrostatic interactions. For all three ETV/PEA3 TADs, there is a rapid 
binding step followed by two conformational changes steps, with each step occurring with similar 
rates of exchange. However, upon further investigation using transient stopped-flow kinetics and 
structural approaches, it was revealed that the slight sequence deviations among the ETV/PEA3 
TADs resulted in significant changes within the conformational ensembles of Med25•TAD 
interactions. Additionally, NMR analysis demonstrated that while the ETV TADs bind to the same 
face of Med25 AcID, they do so in distinct orientations, making contacts with dynamic 
substructures. Additionally, using 15N labeled ETV1 and ETV4 TADs, N-terminal Leu residues in 
proposed disordered regions underwent chemical shifts upon binding to Med25 AcID with L39 of 
ETV1 undergoing a more dramatic shift than L48 of ETV4, showing different engagement of the 
ETV TADs (Fig 3.9).5  
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Figure 3.9: The dynamic regions of ETV/PEA3 TADs bind to Med25 AcID’s dynamic regions in distinct 
orientations.  Top) Chemical shift perturbations induced by ETV/PEA3 binding plotted onto the structure of Med25 
AcID (PDB 2xnf). Circled in cyan is the general orientation of the ETV1/ETV5 and ETV4. Bottom) Chemical shift 
perturbations of 15N ETV1/ETV5 (left) and ETV4 (right) TADs in the absence (blue and orange respectively) and 
presence (light blue and maroon respectively) of unlabeled Med25 AcID. Taken together, these data demonstrate that 
not only do the two TADs engage in unique orientations, but that the implicated dynamic regions of the TADs 
themselves are directly engaging with the dynamic substructures of Med25 AcID. *Data and figure generated by Dr. 
Matthew Henley.  
 
We wanted to test how slight changes in TAD sequences alter the different AcID motifs 
conformational ensembles upon binding due to the changes in sequence in their dynamic regions. 
As described in the previous chapter, ETV5 is an H1 face binder, with key perturbations occurring 
on α3 and β5. Mutations to key residues at these sites attenuated ETV5 binding.11 In Chapter two, 
we showed that while binding affinities and mechanisms are not altered, there is a change in the 
conformational ensembles observed via transient stopped-flow kinetics. Specifically, we showed 
that there was a loss in conformation transitions, with only one observed conformer versus the 
three observed for Med25 AcID. Given the high sequence identity, we hypothesize that a similar 
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trend will be observed with PTOV1A binding to the other ETV/PEA3 TADs; that is, there will be 
a reduction in the number of conformers observed, but with similar affinities.  
We tested PTOV1A against the ETV/PEA3 TADS using transient stopped-flow kinetics. 
As ETV1 behaved similarly to ETV5, we only tested ETV4 and ETV5. Similar Kd’s were observed 
for each system (Table 3.1). Interestingly, PTOV1A when complexed with ERM had only one 
phase, where with ETV4, a second phase was observed. For Med25 AcID, both ERM and ETV4 
observed 3 phases (Figure 3.10). Moreover, each complex demonstrated a unique distribution of 
conformation populations, showing clear differences in the engagement modes of ETV/PEA3 
family members (Table 3.1) For ETV4, PTOV1A shows two distinct conformations, with 90 % of 
the population being observed in the second conformation. Med25, on the other hand, has > 60 % 
of the population in the third conformation (Fig. 3.10). Taken together, these data suggest that 
when comparing the AcID motifs, the sequence changes in the dynamic regions result alters how 






Figure 3.10: Experiments used to define ETV/PEA3 binding parameters. A) Plotted kobs of the fast phase (left) 
and dissociation trace (right) of PTOV1A•ETV4. The association trace (not pictured) was fit to a double exponential. 
For the dissociation trace, 0.5 µM DMN-labeled ETV4 was complex with 2µM PTOV1A, then rapidly mixed with 25 
µM unlabeled ETV4. The trace was fit to a double exponential. For reference, Med25 AcID was fit to a triple 
exponential for both association and dissociation. B) Plotted kobs of the fast phase (left) and dissociation trace (right) 
of PTOV1A•ETV5. The association trace (not pictured) was fit to a single exponential. For the dissociation trace, 0.5 
µM DMN-labeled ETV5 was complex with 2µM PTOV1A, then rapidly mixed with 25 µM unlabeled ETV5. The 
trace was fit to a single exponential. For reference, Med25 AcID was fit to a triple exponential for both association 
and dissociation. C)Equilibruim populations of the AcID•ETV conformations calculated from microscopic 



















Table 3.1: Table of apparent Kd and population distributions for against ETV4 and ETV5  
Complex Kd (µM) C1(%) C2 (%) C3 (%) 
Med25•ETV4 0.7 ± 0.2 9 ± 1  28 ± 3 63 ± 4  
PTOV1A•ETV4 0.25 ± 0.2 10 ± 2 90 ± 8 0 
Med25 ETV5 0.9 ± 0.1 16 ± 3 53 ± 9 31 ± 9 
PTOV1A•ETV5 0.6 ± 0.2 100 0 0 
 
3.3.4 Dynamic regions of TADs and ABDs directly engage with one another  
 
 An emerging hypothesis from the observation that members of the ETV/PEA3 family of 
activators bind to Med25 in unique conformations is that individual ETV•Med25 interactions may 
be differentially affected as a result of conformational shifts in Med25.5  Dr. Amanda Peiffer in 
the Mapp lab showed using molecular dynamic (MD) simulations that the modulation of a loop on 
the Med25 AcID H2 face, shown to be critical for allosteric regulation, induces changes in 
selectivity of ETV/PEA3 transcription factors. Specifically, the MD simulations demonstrated a 
conformational shift in the loop region, Figure 3.11, that altered binding affinity. Mutational 
analysis demonstrated that binding of ETV transcription factors to Med25 in a conformationally-
specific manner. Specifically, the mutant M523E weakened ETV1 and ETV5 binding, while ETV4 
binding was enhanced by approximately 3-fold. These data suggest that this mutation results in 
preferential binding of Med25 to ETV4 over ETV1 and ETV5. Additionally, these data 
demonstrate the direct engagement of TADs to the dynamic regions of ABDs.  
 To study how sequence deviations and changes in allosteric modulation observed in 
PTOV1A will affect ETV binding to this same loop regions, as well identity direct interactions of 
dynamic regions, mutational analysis was also conducted for PTOV1A. The residues identified in 
the MD simulations are conserved in PTOV1A. The mutants S517N and M523E were generated 
PTOV1A•ETV4 
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and tested against FITC-labeled ETV4 and ETV5. S517N, located directly in the loop region, 
showed no significant changes in binding affinity. However, M523E weakened binding affinity 
for both ERM and ETV4 by 2-fold. Given that there is an overall loss in structure, this is not too 
surprising. These changes in binding affinity, as seen with the equivalent M523E mutant made to 
PTOV1A demonstrate that changes in conformations can alter binding, and that dynamic 
substructures play a role in binding.  
  
  
Figure 3.11: Direct engagement of dynamic regions between ABDs and TADs. Top left demonstrates the 
molecular dynamic simulations that show changes in conformation in the allosteric loop (shown above the yellow 
sphere that represents the Med25M523E mutant). These data were generated by Dr. Amanda Peiffer. The top middle 
graph shows the changes in affinity induced by the mutant. These data were generated by Dr. Matthew Henley. The 
top right figure shows the location of the PTOV1A mutants generated. S517N is located in the proposed allosteric 
loop, and by adding a bulkier residue, the loop may pulled down. M523E is located below, with the introduction of a 
charged residue proposed to pull down the loop region. The bottom figures show the binding curves, with error 
reported as the standard deviation.  
 
3.4 Conclusions and Assessment 
These ‘fuzzy interactions’ have long been termed undruggable due to the evasive nature in 
studying by traditional means. While it was originally proposed that binding was driven through 
electrostatic and hydrophobic interactions, this model does not account for the intricate specificity 
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S515N Κd = 0.012 ± 0.05µM 
M523E Κd = 0.24 ± 0.5µM 
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and selectivity required for such a highly regulated process as transcription initiation. Towards this 
end, recent work in the Mapp lab has demonstrated that molecular recognition is driven through 
conformational changes driven through dynamic regions.  Upon activator binding to the ABD, 
there is a winnowing of conformers, allowing a unique state specific to each interaction.    
In this chapter, we investigate how hotspots can be used to differentiate highly similar TAD 
sequences. Using two TADs from the ETV/PEA3 family of transcription factors, we tested how 
slight sequence deviations can lead to changes in conformation of AcID motifs. Given that these 
TADs are highly related, this system served as an opportunity to demonstrate mechanism 
specificity. Using in depth transient kinetic analysis, we demonstrated that not only is there a high 
degree of specificity of TAD recognition within one coactivator, but that the different AcIDs 
exhibit different conformational ensembles. Small changes in TAD sequence resulted in a high 
degree of specificity. These changes in conformations is mediated by the high degree of plasticity 
in the AcIDs. Moving forward, testing PTOV1B against the ETV/PEA3 TADs can provide further 
insight into each AcID motif responds. Additionally, HSQC NMR experiments to explore how 
each TAD interacts with the different AcID motifs can provide powerful insight molecular 
recognition of these complexes.  
Additionally, we tested how modulators can be used to target hotspot residues. GA, a natural 
product, while not a covalent labeler, was found to show a range of different IC50 values, with 
PTOV1A showing a tighter IC50. These data suggest that the changes in dynamic structures can be 
used as an asset, allowing for selective targeting. Testing against PTOV1B, as well as an in-depth 
kinetic analysis to determine how koff is affected will further help exploit hotspots. Taken together, 
the work in this chapter demonstrates that the nonspecific model of recognition is outdated. 
Through this work, we begin to demonstrate that the AcID motifs utilize their differences in 
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dynamic substructures to recognize different binding partners. Given their overall plasticity, we 
can use these less conserved allosteric regions to selectively and specifically target these ABDs.  
Typically, PPI interfaces are highly polar and often conserved, making it difficult to target 
orthosterically while achieving selectivity and specificity.  Use of allosteric modulators that can 
bind to dynamic hot spots can induce conformational changes that can inhibit or enhance binding.18  
Allosteric modulators that target dynamic hot spots can act as chemical probes that can be used to 
dissect binding mechanisms. Moving forward, it is critical to continue testing allosteric modulators. 
One such modulator is the covalent inhibitor norsticitic acid (NA) (Fig. 3.12). NA is a depsidone 
containing orthophenolic aldehyde moiety that modulates Med25 AcID via a covalent mechanism 
via imine formation with Lys side chains. Specifically, NA covalently labels a Lys rich loop on 
the H2 binding face. Extensive work led by Dr. Julie Garlick and Dr. Steven Sturlis demonstrate 
an IC50 against ERM of 2.1 µM. Binding of NA thus induces an allosteric change by inducing a 
slight unfolding of the two dynamic loops on the H1 face, as shown through molecular dynamic 
simulations led by Amanda Peiffer. Work is currently underway to determine how sequence 
deviations of the dynamic regions amongst the AcID motifs are thus affected by NA binding.  
Figure 3.12: Norstictic acid is a covalent modulator of AcID motifs. On the left structure of norstictic acid, an 
orthophenolic aldehyde containing depsidone.  On the right structure of Med25 AcID highlighting the triple Lys loop 
that is preferential labeled. Specifically, NA labels K519.  
 
Transcriptional activators and coactivators have long been considered “undruggable” due 
to the difficulty with which they are targeted by small molecules.19 For example, AcID is a 
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challenging system to target.4,15 Given its rather featureless binding interface coupled with binding 
to multiple binding partners over transient, short-lived interactions, it is perhaps not surprising that 
there has only been one reported successful discovery of a small-molecule ligand.20 To compound 
this issue, there contains a second AcID containing protein in humans, PTOV1, with high sequence 
conservation, although there is differentiation in the dynamic regions (Fig. 3.2).21,22 Dysregulation 
of both Med25 AcID and PTOV1 result in disease states, such as prostate cancer, and it is thus 
critical to selectively target the AcID motifs.21,22 Like other coactivators, the presence of dynamic 
loops and helices in the AcID motif have been hypothesized by our group to present better biding 
















3.5 Materials and methods  
Plasmids for protein expression  
 Prof. Patrick Cramer generously provided the Med25 expression plasmid pET21b-Med25 
(394-543)-His6. Plasmid sequence identity was confirmed via standard Sanger sequencing 
methods on an Applied Biosystems 3730xl DNA Analyzer at the University of Michigan DNA 
Sequencing Core and analyzed using SeqMan Pro from the Lasergene DNASTAR software suite.  
 pET21b plasmids for PTOV1A (88-235) and PTOV1B (253-398) were purchased from 
Genescript. Both plasmids contain a C-terminal 6x His tag. Plasmid sequence identity was 
confirmed via standard Sanger Sequencing as described above.   
 Quick-change site-directed mutagenesis was used to create the PTOV1A mutants. Identity 
was determined by Sanger Sequencing. The primers for SDM are as shown in Table 3.2 
Table 3.2 Primers used for site-directed mutagenesis of PTOV1A 
Plasmid Primer Sequence  
pET21b-PTOV1A S517N-His6 F: CTGCTGTACAGCAACAAGAAAAAGATCTTC 
R: GAAGATCTTTTTCTTGTTGC GTACAGCAG 
pET21b-PTOV1A M523E-His6 F: AAGAAAAAGATCTTCGAGGGTCTGATTCCG 
R: CGGAATCAGACCCTCGAAGATCTTTTTCTT 
 
Expression and purification of CBP GACKIX 
CBP GACKIX was expressed and purified using previously described protocols.23 
Expression of Med25 AcID  
Med25 AcID and was expressed as follows. Plasmids were transformed into chemically 
competent Bl21-AI cells (Novagen), plated onto LB/ampicillin/streptomycin agar, and incubated 
at 37˚C overnight. The next day, plates were stored at 4˚C until further use. In the evening, a single 
colony from the plate was selected and placed in 50 mL of Terrific Broth (TB) with 0.1 mg/mL 
ampicillin and 0.05 mg/mL streptomycin and incubated at 37˚C at 250 RPM. The following 
morning, 5 mLs from the starter culture was added to 1L TB with 0.1 mg/mL ampicillin and 0.05 
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mg/mL streptomycin and was grown to an OD600 of 0.6-0.8 at 37˚C, 250 RPM. Once OD600 was 
reached, temperature was reduced to 20˚C for a minimum of thirty minutes before induction. Cells 
were induced with 0.250 mM IPTG and 2% arabinose. Bacteria were shaken overnight at 20˚C, 
250 RPM. The next morning, cultures were centrifuged at 7000 x g for 20 minutes at 10˚C. Cell 
pellets were stored at -80˚C until purification.  
Expression of PTOV1A and PTOV1B and mutants  
 pET21b-PTOV1A(88-235)-His6 (including PTOV1AS517N and PTOV1AM523E) and 
pET21b-PTOV1B(253-398)-His6 were expressed using the same method. Plasmid was 
transformed into chemically competent Bl21-AI cells, plated onto LB/ampicillin/streptomycin 
agar and incubated overnight at 37˚C. The next day, plates were stored at 4˚C until needed. In the 
evening, a single colony was selected and added to 50 mL of TB with 0.1 mg/mL ampicillin and 
0.05 mg/mL streptomycin and incubated overnight at 37˚C, 250 RPM. The following morning, 7 
mLs from the starter were added to 1 L TB with the same concentrations of antibiotics used for 
the overnight and grown to an OD600 of 1.0 at 37˚C, 250 RPM. Once OD600 was reached, the 
temperature was reduced to 30˚C for at least 30 min before induction. Cells were induced with 
0.300 mM IPTG and 2% arabinose. Bacteria were shaken overnight at 30˚C, 250 RPM. The next 
morning, cultures were centrifuged at 7000 x g for 20 minutes at 10˚C. Cell pellets were stored at 
-80˚C until purification.   
Purification of expressed proteins.   
 All proteins were purified using the same FPLC purification methods and were subjected 
to affinity and ion exchange chromatography. Frozen cell pellets were thawed and resuspended in 
lysis buffer (50 mM phosphate, 300 mM NaCl, 10 mM imidazole, pH 6.8, 0.7 µL/mL β-ΜΕ, 1 
protease inhibitor tablet) and lysed via sonication. Cellular debris was pelleted by centrifugation 
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for 20 min at 9500 RPM. The clear cell lysate was then subjected to one more round of sonication 
to help breakup DNA, and then centrifuged again. Supernatant was filtered using 0.45 µM syringe 
filter (CellTreat) and loaded directly onto an AKTA Pure FPLC with a 5 mL Ni-NTA column 
(HisTrap HP, GE Healthcare) using a gradient of 100% Buffer A (50 mM sodium phosphate, 300 
mM NaCl, and 30 mM imidazole, pH 6.8) to 100% Buffer B (50 mM sodium phosphate, 300 mM 
NaCl, and 500 mM imidazole, pH 6.8) over ten column volumes. AcID-containing fractions were 
polled and underwent a second purification via cation exchange (HiTrap SP HP, GE Healthcare) 
with a gradient of 100% Buffer A (50 mM sodium phosphate, 1mM DTT, pH 6.8) to 100% Buffer 
B (50 mM sodium phosphate, 1 M NaCl 1mM DTT, pH 6.8) over fifteen column volumes. 
Fractions containing purified protein were pooled and dialyzed into storage buffer (10 mM sodium 
phosphate, 100 mM NaCl, 0.001% NP-40, 1% glycerol, 1mM DTT, pH6.8). Following dialysis, 
protein concentration was determined via UV/Vis spectroscopy on a NanoDrop at 280 nm using 
an extinction coefficient, ε=22,460 M-1cm-1. Protein identity was confirmed via mass spectrometry 
(Agilent QToF) and purity was assed via SDS-PAGE on a 4-12% bis-tris gel stained using Quick 
Coomassie (Anatrace). Purified protein was aliquoted, snap frozen, and stored at -80˚C.  
Expression and purification of CBP GACKIX 
CBP GACKIX was expressed and purified using previously described protocols.23 
Direct binding experiments  
 Direct binding experiments measured by fluorescence polarization were performed in 
triplicate. Final sample volume was 20 µL in a low volume, round bottom, non-stick, 384-black 
well plate (Corning). FITC labeled peptides were diluted in binding buffer (5 mM sodium 
phosphate, 100 mM NaCl, 10% glycerol, 0.001% NP-40, pH 6.8) to 40 nM. 10 µL Protein was 
serially diluted two-fold with assay buffer going down the plate, allowing for eight total 
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concentration readings per experiment. The final well was a negative control, peptide only. 10 µL 
of diluted peptide was then added to each well for a final concentration of 20 nM. The plate was 
then incubated for 30 min at room temperate before fluorescence polarization was read on  
PHERAstar plate reader (polarized excitation at 485 nM and emission intensity measured through 
a parallel and perpendiculary polarized 535 nM filter. 
 GraphPad Prism was used to calculate the apparent KD and indicated error (SDOM) via the 
equation below. A binding isotherm that accounts for ligand depletion, assuming a 1:1 binding 
model), was fit to the observed values as a function of protein in order to obtain the apparent 
equilibrium constant, where ‘a’ and ‘x’ are the total concentrations of fluorescent peptide and 
protein, respectively. ‘b’ is the maximum observed polarization value, and ‘c’ is the minimum 
value.  
𝑦 = 𝑐 + (𝑏 − 𝑐) ×
[(𝐾! + 𝑎 + 𝑥) − .(𝐾! + 𝑎 + 𝑥)" − 4𝑎𝑥
2𝑎  
Fluorescence polarization competition assays 
Inhibition assays were performed in triplicate with a final sample volume of 20 µL in a low volume, 
non-binding 384-well black plate (Corning). Protein was precomplexed with fluorescent (FITC) 
peptide using two-fold the concentrations of protein and peptide in order to reach 50% of the tracer 
bound in binding buffer (5 mM sodium phosphate, 100 mM NaCl, 10% glycerol, pH 6.8). Small 
molecule, dissolved in DMSO and diluted in assay buffer was serially diluted down two-fold with 
assay buffer going down the plate. 10 µL of the pre-complexed peptide-protein complex was then 
added to each well for a final volume of 20 µL. The final well, row P, served as a negative control, 
tracer only. The plate was incubated for thirty minutes at room temperature before fluorescence 
polarization was measured on a PHERAstar plate reader. The experiment was conducted using 
polarized excitation at 485 nm and emission intensity was measured through a parallel and 
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perpendicularly polarized 535 nm filter. Polarization values were converted to relative fraction 
bound and plotted against log[inhibitor]. Inhibition curves were then fit to a non-linear regression 
using Prism’s ‘log(inhibitor) vs response – variable slope’ equation from which the IC50 values 






Transient kinetic experiments  
 Stopped-flow kinetic assays were performed on a Kintek SF-2001 stopped-flow equipped 
with a 100 W xenon arc lamp in two syringe mode. The 4-DMN fluorophore was excited at 440 
nm and its emission was monitored at wavelengths greater than 510 nm, using a long-pass filter 
(Corion). All experiments were run at 10˚C in buffer (10 mM sodium phosphate, 100 mM NaCl, 
1% glycerol, 0.001% NP-40, pH 6.8), and solutions were allowed to equilibrate on the instrument 
for at least five minutes before the experiment was run. Concentrations reported are after rapid 
mixing. All kinetic traces are an average of 40-80 individual traces, and in triplicate. Error reported 
is standard deviations. A series of exponential equations were fit to the transient kinetic time 
courses, F(t) as described in the below equation, to obtain fluorescence amplitude (Fn) and the 
observed rate constants (kobs) for each exponential phase, where F∞ is the final fluorescence 
intensity and t=time.  
𝐹(𝑡) = 𝐹# + 𝛴𝐹$	 ×	(1 − 𝑒&'!"#,$×*) 
 Association experiments were performed by mixing excess protein with a constant 
concentration of labeled activator. Dissociation experiments were performed by precomplexing 
protein with labeled activator and mixing with excess of the corresponding unlabeled activator. 
The concentrations of the association experiments are as follows: 50 nM VP16, 125 nM ATF6α, 
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and 250 nM ERM. The concentrations for the dissociation experiments are as follows: 50 nM 
labeled VP16, 100 nM protein, 10 µM unlabeled VP16; 250 nM labeled ATF6α, 500 nM protein, 
10 µM unlabeled ATF6α; 500 nM labeled ERM, 1µM protein, 50 µM unlabeled ERM. The labeled 
activator concentrations in both association and dissociation experiments were chosen to maximize 
S/N and minimize ligand depletion effects in the association experiments.  
Calculation of Rate Constants  
 The individual kobs,n values were plotted as a function of concentration and fit to a square 
hyperbola (equation below) in order to determine the maximal observed rate constant (kobs,n,max) 
and the half maximal concentration (K1/2,n). The value of kobs,n,min was included for the fit, but not 
for calculations as it is defined by the corresponding kobs,n,off. The microscopic rate constants were 




+ 𝑘+,-,$. 3$ 
 A rapid equilibrium and steady-state approach was used to determine rate parameters. For 
simplicity sake, the method for calculating the microscopic rate constants is split into two sections: 
the initial binding step in which C1 transitions into C2, and the transition of C2 to C3. The first 
two steps, we can determine the maximal observed rate constant of the first conformational change 
(kobs,2,max) using the following equation. In all cases, kobs,1,off  is well defined for PTOV1A.  
 
𝑘+,-,",./4 = 𝑘5,0 +	𝑘6,0 
 Using steady-state approximation, the corresponding observed rate constant for the 
dissociation (kobs,2,off) is as follows:  





 Koff can be calculated using the observed rate constants from dissociation experiments 
(kobs,n,off) as follows:  
𝑘+77 = 𝑘+,-,0,+77 + 𝑘+,-,",+77 − 𝑘+,-,",./4 
 Since we only observed two conformations, we do not need to consider the transition from 
C2 to C3. Relative populations C1 and C2 (for PTOV1A) at equilibrium were then determined by 
the conformational equilibrium constants (K,c,n = kF,n / kR,n), which are ratios between the 
conformational states, by definition. Below are the equations used to calculate the populations of 
each states. C1 is serving as the references state. Only the relative conformational populations of 
the bound state were considered, thus all values are concentration dependent.  
In all cases, kobs,1,off  is well defined for PTOV1A.  
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛	𝐶1 = 	
1




1 + 𝐾8,0 + O𝐾8,0 × 𝐾8,"P
× 100% 
 
Solid-phase peptide synthesis and purification 
Table 3.3 Sequence of peptides used in this study  
Entry  Peptide Sequence  
1 VP16(438-490) AcALDDFDLDMLGDGDSPGPGFTPHDSAPYGALDMADFEFEQMFTDALGI 
DEYGG 
2 ATF6α(38-75) AcFTDTDELQLEAANETYENNFDNLDFDLDLMPWESDIWD 
3 ΕRM(38-68) AcDLAHDSEELFQDLSQLQEAWLAEAQVPDDEQ 





























4-DMN- βAla- LPPLDSEDLFQDLSHFQETWLAEAQVPDSDEQ 
 The peptides listed in Table 3.2 were made using standard FMOC solid-phase synthesis 
methods on a Liberty Blue Microwave Synthesizer (CEM). Deprotection of the FMOC groups 
were done in 20% piperidine (ChemImpex) in DMF that was sumplemented with 0.2 M Oxyma 
Pure (CEM) and irradiating under variable power to maintain a temperature of 90˚C for one minute. 
For coupling reactions, 5 eq of amino acids relative to resin (CEM, ChemImpex, and 
NovaBiochem) were added to diisopropylcarbodiimide  (7 eq, ChemImpex) and Oxyma Pure (5 
eq) in DMF and irradiated at variable power to maintain a temperature of 90˚C for 4 minutes. 
Between all couplings and deprotections, the resin was rinsed four times with excess DMF.  
 Following synthesis, peptides 1-4 were deprotected one final time and acetylated at the 
amino terminus using a cocktail of acetic anhydride and triethylamine (Fisher Scientific) in 
dichloromethane. Peptides 5-8 were deprotected one final time following synthesis, and then 
treated with fluorescein isothiocyanate (FITC, ThermoFisher) in the presence of N,N-
diisopropylethylamine (Sigma Aldrich). The remaining peptides were deprotected and then 
subjected to one final coupling N-terminally to 4-DMN linked to a β-alanine prior to cleavage. All 
peptides were cleaved in 95% trifluoroacetic acid (Sigma Aldrich), 2.5% H20 and 2.5% 
triisopropylsilane (Sigma Aldrich) for four hours, then filtered. The remaining solution was 
concentrated under nitrogen and precipitated in cold diethyl ether.  
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  The precipitated peptide was dissolved in 50/50 0.1% TFA in water and acetonitrile with 
minimal ammonium hydroxide to help with solubility, syringe filtered using a 0.45µn, and purified 
via HPLC purification. The peptide was purified using reversed phase HPLC on an Agilent 1260 
Series instrument with a 250  x 10 mm Luna Omega 5 µm PS C18 column (Phenomenex) using a 
gradient elution of acetonitrile in 0.1% TFA in water. Purified peptide were tested for purity using 
analytical HPLC, and identity was determined via mass spectrometry under negative ion mode 
(Agilent ToF). Once determined to be pure, peptides were dissolved in minimal DMSO and 
quantified via UV/Vis spectroscopy using either Tyr absorbance at 280 for acetylated peptides 
(ε280=1,280M-1cm-1), FITC absorbance at 495 nm (ε495=72,000 M-1cm-1), or 4-DMN absorbance 
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Conclusions and Future Directions 
 
4.1 Summary 
 The work presented in this thesis aims to expand the view of binding mechanisms and 
molecular recognition of coactivator activator binding domains (ABDs).  Specifically, we look to 
understand the mechanisms by which β-barrel containing ABD homologs form protein-protein 
interactions (PPIs), with transcriptional activators. This work sheds light on how sequence 
deviations in the dynamic substructures of a unique coactivator motif affect conformational 
changes and allostery.  
 Historically, it has been proposed that molecular recognition occurs over nonspecific 
interactions, largely driven by electrostatics.1  Activators were proposed to dictate molecular 
recognition by recognizing DNA sequences through their DNA binding domains.2,3  Early data 
suggested that the transcriptional activation domain (TADs) of activators were largely unstructured 
in their free state, supporting the notion that there is a lack of specific interactions with coactivator 
binding partners.4  Moreover, the only identifiable sequences among TADs were the presence of 
acidic and hydrophobic residues.4,5 It was hypothesized that any specificity of recognition came 
from activator localization to the DNA, or even co-localization events.  Once bound to the genomic 
loci, the DNA-bound activators could then recruit the other components to then initiation 
transcription.4,6 This model thus suggests that ABDs can bind to different TADs as a result of the 
TADs promiscuous behavior.7–9 
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 A competing theory to this model suggests more specificity. Often largely ignored, 
coactivator ABDs play a critical role in molecular recognition. In the model arguing for more 
specificity, TADs recognition occurs through flexible, intrinsically disordered, nature of the TAD 
allowing for it to adapt to the surface of its cognate binding partner. More specifically, this would 
mean that TADs are adapting the topology of ABDs, fitting into the hydrophobic grooves and 
charged regions of the ABD.10,11 Even in nonspecific models, ABDs are highly implicated for the 
binding mechanisms, with posits that ABDs are nothing more than featureless surfaces, largely 
hydrophobic binding interfaces that interact with the negatively charged sidechains of the TAD.9  
 Deviating from this model of non-specificity is one that highly implicates the role of ABDs. 
It is well accepted that TADs undergo a coupled folding and binding, but ABD’s ability to undergo 
significant conformational changes has largely been ignored.  Structural studies of the ABD KIX 
have demonstrated that KIX can adopt unique conformations themselves when binding to different 
activators, suggesting that ABDs can adapt to each TAD. 11,12,13  
 Recently the Mapp lab has thoroughly examined the molecular recognition model of 
transcriptional PPIs using the structurally distinct ABD from the Mediator subunit Med25.14,15 It 
was originally proposed that the barrel region, an unusual feature in ABDs, was critical for 
activator recognition.16 Extensive biophysical and structural work has shown, however, that it is 
the dynamic regions of the ABD, similar to that of KIX, that are undergoing conformational 
changes to accommodate TAD binding.  Furthermore, by using a family of highly similar TADs, 
surprising specificity was observed in ABD recognition, with slight sequence deviations result in 
a significant degree of conformational sensitivity of AcID.  
 In this thesis, we examine the binding mechanisms of a unique coactivator ABD, termed 
Activator Interaction Domain (AcID). This ABD consists of a seven stranded β-barrel flanked by 
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α-helices and loops. Specifically, we examine three AcID paralogs that share high sequence 
identity but deviate in their dynamic substructure. Using a biophysical approach, we explore how 
changes in sequence of these dynamic regions affect activator binding and the concurrent 
conformational change of the ABD upon binding.  
Sequence deviations of dynamic substructures alter conformations upon binding 
In chapter two, we dissect how dynamic substructures affects molecular recognition within 
AcID motifs using AcID paralogs found in Med25 and PTOV1, a second protein in humans that 
contains two tandem AcID motifs.17,18  These proteins share high sequence identity but deviate in 
sequence in their dynamic regions.  We use a biophysical approach to explore how these sequence 
deviations alter the binding mechanisms in complexing with transcriptional activators. Our guiding 
hypothesis was sequences deviations would alter binding selectivity and the conformational 
changes of the resulting complexes. We demonstrate that while overall the binding affinities and 
mechanisms are conserved, we see a loss in conformation states. This is likely due to the loss in 
secondary structure of the PTOV1 AcIDs, resulting in lower energy between conformations and 
therefore making it difficult to discern different conformations using current methods. Together, 
these data suggest there is a degree of specificity in binding amongst the AcID motifs. 
We show that sequences changes in the dynamic substructures alter the conformations. 
PTOV1 has been observed to outcompete Med25 for binding to CBP when overexpressed in 
metastatic prostate cancer, these changes in sequence are highly implicated in function.  
Specifically, the changes in conformational plasticity as a result of the sequence deviations may 
alter transcriptional output by altering the AcID•activator complex formation timescale. Due to its 
large role in many cancer states, it is crucial to determine PTOV1’s role in modulating transcription, 
as well as further dissect its antagonistic behavior.  
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Dynamic substructures dictate allostery and recognition  
In chapter three, we use the AcID paralogs to determine how sequence deviations in the 
dynamic regions will alter allosteric communication. We establish that allosteric communication 
is conserved in the AcID motifs, but that PTOV1A has a shorter-lived ternary complex compared 
to Med25 AcID. Using this information, we look at how changes in the dynamic substructures 
alter allosteric modulator binding. Using the natural product garcinolic acid, we demonstrate it is 
capable of allosterically inhibiting ERM binding and is more potent against the PTOV1A-ERM 
than Med25’s interaction with ERM.  Additionally, we investigate how hotspots can be used to 
differentiate highly similar TAD sequences by using a biophysical approach to examine how slight 
changes in TAD sequence can result in differential changes in coactivator conformations. 
Specifically, we tested how slight sequence deviations can lead to changes in conformation of 
AcID motifs. Given that these TADs are highly related, this system served as an opportunity to 
demonstrate mechanism specificity. 
The work in this chapter demonstrates that the nonspecific model of recognition is outdated. 
Through this work, we begin to demonstrate that the AcID motifs utilize their differences in 
dynamic substructures to recognize different binding partners. Given their overall plasticity, we 
can use these less conserved allosteric regions to selectively and specifically target these ABDs. 
Protein-protein interactions between activators and coactivators have long been termed 
undruggable due to the difficult nature in studying by traditional means.  While it was originally 
proposed that binding was driven through electrostatic and hydrophobic interactions, this model 
does not account for the intricate specificity and selectivity required for such a highly regulated 
process as transcription initiation. Towards this end, recent work in the Mapp lab has demonstrated 
that molecular recognition is driven through conformational changes driven through dynamic 
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regions.  Given their role in disease it is critical to identify small molecule inhibitors that can 
selectively target the different AcID motifs.18–20 
4.2 Future Directions 
The role of PTOV1 in modulating transcription  
 The AcID motif has only been identified in higher eukaryotic organisms. In fact, it has only 
been identified in one other protein aside from Med25, Prostate Tumor Overexpressed Variant 1 
(PTOV1).  PTOV1 was identified using differential display screening methods.  Work by the Um 
group identified PTOV1 as having two tandem AcID motifs, termed PTOV1A and PTOV1B (Fig. 
4.1).  Sequence alignments to Med25’s AcID showed PTOV1A and PTOV1B share 81% and 71% 
sequence identify, respectively.  This raised the question of the role of PTOV1’s two AcID motifs. 
PTOV1 was not found to associate with the Mediator complex, and was found originally to be 
overexpressed in primary tumors and early prostate cancer patients.  In most healthy cells, PTOV1 
is undetectable, but has since been shown to be overexpressed in a variety of early and late stage 
cancers.  
Figure 4.1: Domain architect and structure of the AcID containing proteins. On the left is the domain layout of 
Med25 and PTOV1. On the right is the structure of Med25 AcID (PDB 2xnf). 
  
Extensive research has demonstrated that PTOV1 plays a variety of roles, acting as an 
‘adaptor protein,’ that can regulate gene expression at both the transcriptional and translational 
levels.18,21,23 One proposed role, and a role relevant to the work in this thesis, is that PTOV1 can 
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act as a negative regulator of Med25 AcID function. When overexpressed, PTOV1 was found to 
block the Med25•CBP interaction. Specifically, PTOV1 was found to bind to outcompete Med25 
binding to CBP, thus preventing Med25 from binding to CBP at the retinoic acid receptor (RAR) 
in the presence of retinoic acid (Fig 4.2).17,24  Moreover, reports suggest that PTOV1, while 
undetectable in most normal cell tissues, is overexpressed in a wide-range of early and late stage 
cancers.18,21,25 These studies highlight that it is critical to study PTOV1’s biological function. Not 
only would it provide insight into a variety of disease states, but it can lead to further discovery of 
Med25 function and regulation.  
 
Figure 4.2: Binding events of Med25/CBP activity in the presence and absence of PTOV1. In healthy cells, the 
presence of retinoic acid allows for the repressor to be removed from RAR, allowing for Med25 to bind to CBP 
through its AcID domain and to RAR through its NR. CBP also binds to RAR. However, in metastatic prostate cancer, 
overexpressed PTOV1 binds to CBP, blocking it from binding to Med25.  
 
Recently it has been discovered that both AcID domains in PTOV1 contain nuclear 
localization sequences.25 This information, coupled with the emergent data from this thesis, poses 
the question of PTOV1’s role in modulating transcription. Specifically, it would be critical to look 
at the role of the two AcID motifs, as we have demonstrated that the sequence deviations in the 
dynamic regions results in different conformational signatures upon TAD binding. One proposed 
hypothesis is that PTOV1 is using one AcID motif to localize to the genomic loci, either directly 
to the DNA or to other transcription factors, and the other is binding to the rest of the transcriptional 
components, thus bypassing the need for the Mediator complex.  
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One way to test this hypothesis is to utilize a mammalian two-hybrid system using the 
prostate cancer cell PC-3, which has high mRNA levels of PTOV1.26,27 Another option would to 
conduct an in vitro transcriptional assay. Specifically, by using nuclear extracts from Med25 
knockouts derived from patient derived VARI068 cells, we can determine not only if PTOV1 can 
activate transcription, but further probe the proposed squelching mechanism PTOV1 utilizes to 
outcompete Med25.28–30  Given PTOV1’s role in cancer, it is critical to find inhibitors that can 
selectively target one AcID motif over the other.  One potentially powerful method is to utilize 
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Initial Discovery and Characterization of Garcinolic Acid1 
 
Garcinolic acid (GA), a xanthone natural product isolated from Garcinia, was originally 
identified as an inhibitor of CBP KIX (Fig. A.1). Working with Dr. Meghan Breen, GA emerged 
from library screen of more than 5900 compounds comprised of natural products, FDA-approved 
drugs and bioactive molecules using a competitive-inhibition binding assay. The screen was 
originally conducted using Med15 KIX from Saccharomyces cerevisiae (sc) and Candida galbrata 
(cg). However, when we conducted follow-up screening using a fluorescence polarization-based 
competition assay and found that GA is highly selective for the CBP GACKIX motif, only 
modestly inhibiting Gal11/Med15 KIX complexes, and not interacting at all with Arc105 KIX 
















Figure A.1: Garcinolic acid and the various KIX motifs. Pictured above are the structures of KIX from various 
organisms, including yeast, as well as garcinolic acid. Additionally, we demonstrate that GA potently inhibits CBP 
KIX-MLL interactions.  
 
We demonstrate that GA is a potent inhibitor and shows preferential inhibition to 
CBP/p300 KIX. Several lines of evidence indicated that GA was a reversible, noncovalent 
inhibitor of KIX, despite the presence of at least two potentially reactive site. No detectable 
covalent adducts were observed via mass spectrometry, even after extended incubation. Moreover, 
transient stopped-flow experiments conducted by Dr. Matthew Henley reveals a reversible binding 
mechanism.  
Table A.1: Summary of the inhibitory effects of GA against various KIX domains. Half maximal inhibitory 
constants of GA for tested TAD•ABD PPIs. Data is in triplicate and reported error is the standard deviation. (Data 
obtained with the help of Dr. Meghan Breen).  
 
Coactivator Domain TAD IC50 (µM) 
scMed15 KIX Pdr1 27 
























) IC50= 5.6± 0.4µM 
IC50= 9.1± 2µM 
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CBP KIX MLL 3.3 ± 0.9 
CBP KIX c-Myb 4.5 ± 1 
p300 KIX MLL 4.6 ± 1 
p300 c-Myb 7.2 ± 2 
 
 GA inhibited MLL and cMyb TADs with similar IC50 values despite their binding to 
opposite binding faces. As stated in earlier chapters, there exists a well characterized allosteric 
network between these two binding faces. Due to the observation GA inhibiting both TADs, this 
raised the question of whether GA orthosterically bound to one face and induced inhibition at the 
second site via allostery. Through extensive analysis using HSQC and Protein-Observed 19F 
(PrOF) NRM completed by Dr. Matthew Beyersdorf, GA was shown to engage at the MLL binding 
site, thus blocking the binding of this TAD (Fig. A.2). Additionally, perturbations were observed 
at the conformationally dynamic loops that flank the MLL binding site. Therefore, it is not 
surprising that GA engagement to the MLL site also inhibits c-Myb binding. In fact, the 
conformation created from GA-KIX engagement resembles a previously reported conformation 
that is shown to disfavor binding to the c-Myb site. Taken together, these initial data demonstrate 
that GA has the potential to serve as a powerful chemical probe to explore the binding mechanisms 
of CBP/p300 KIX. We show that GA is capable of orthosteric and allosteric inhibition, and this 




Figure A.2: GA binds near the MLL site and allosterically inhibits c-Myb binding. NMR experiments conducted 
by Dr. Matthew Beyersdorf reveal that GA causes significant chemical shift perturbations near the MLL site. HSQC 
NMR perturbations are shown in red, and the only 3FY residue that was perturbed in PrOF NMR was Y631 on the 






































Materials and Methods 
 





























Analytical HPLC trace of Ac-ETV4 (45-76) monitored at 280 nM. Analytical sample was run in 
a water (with 100 mM ammonium acetate)/acetonitrile system.  The sample was injected with an 
isocratic flow of 70% water (with 100mM ammonium acetate) and 30% acetonitrile. After 2 mins, 
the solvent gradient was increase from 10-35% acetonitrile over 20 mins.  
LC-MS of Ac-ETV4 (45-76) using an Agilent TOF. Samples were run in 50/50 0.1% TFA in 
water, and acetonitrile. Samples were injected onto a C8 column with a C4 guard. Identity was 
confirmed under negative mode ionization conditions.  
 
Analytical HPLC trace of DMN-ETV4 (45-76) monitored at 440 nM. Analytical sample was run 
in a water (with 100 mM ammonium acetate)/ acetonitrile system. The sample was injected with 
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an isocratic flow of 70% water (with 100 mM ammonium acetate) and 30% acetonitrile. After 2 
mins, the solvent gradient was increased from 10-50% acetonitrile over 40 mins.  
 
LC-MS of 4-DMN-ETV4 (45-76) using an Agilent TOF. Samples were run in 50/50 0.1% TFA 
in water, and acetonitrile. Samples were injected onto a C8 column with a C4 guard. Identity was 
confirmed under negative mode ionization conditions. 
 
Analytical HPLC trace of FITC-ETV4 (45-76) monitored at 495 nM. Analytical sample was run 
in a water (with 100 mM ammonium acetate)/ acetonitrile system. The sample was injected with 
an isocratic flow of 70% water (with 100 mM ammonium acetate) and 30% acetonitrile. After 2 
mins, the solvent gradient was increased from 10-50% acetonitrile over 40 mins.  
LC-MS of FITC-ETV4 (45-76) using an Agilent TOF. Samples were run in 50/50 0.1% TFA in 
water, and acetonitrile.  Samples were injected onto a C8 column with a C4 guard. Identity was 
confirmed under negative mode ionization conditions. 



















Analytical HPLC trace of Ac-ERM (38-68) monitored at 280 nM. Analytical sample was run in a 
water (with 0.1% TFA)/ acetonitrile system. The sample was injected with an isocratic flow of 
50% water (with 0.1% TFA) and 50% acetonitrile. After 2 mins, the solvent gradient was increased 
from 10-50% acetonitrile over 40 mins.  
 
LC-MS of Ac-ERM (38-68) using an Agilent TOF. Samples were run in 50/50 0.1% TFA in 
water, and acetonitrile.  Samples were injected onto a C8 column with a C4 guard. Identity was 
confirmed under negative mode ionization conditions. 
 
Analytical HPLC trace of FITC-ERM (38-68) monitored at 440 nM. Analytical sample was run 
in a water (with 0.1% TFA)/ acetonitrile system. The sample was injected with an isocratic flow 
of 50% water (with 0.1% TFA) and 50% acetonitrile. After 2 mins, the solvent gradient was 
increased from 10-50% acetonitrile over 40 mins.  
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LC-MS of FITC-ERM (38-68) using an Agilent TOF. Samples were run in 50/50 0.1% TFA in 
water, and acetonitrile.  Samples were injected onto a C8 column with a C4 guard. Identity was 
confirmed under negative mode ionization conditions. 
 
 
Analytical HPLC trace of 4-DMN-ERM (38-68) monitored at 440 nM. Analytical sample was run 
in a water (with 0.1% TFA)/ acetonitrile system. The sample was injected with an isocratic flow 
of 50% water (with 0.1% TFA) and 50% acetonitrile. After 2 mins, the solvent gradient was 
increased from 10-50% acetonitrile over 40 mins.  
 
LC-MS of 4-DMN-ERM (38-68) using an Agilent TOF. Samples were run in 50/50 0.1% TFA 
in water, and acetonitrile.  Samples were injected onto a C8 column with a C4 guard. Identity 
was confirmed under negative mode ionization conditions. 












Analytical HPLC trace of Ac-L2L3 VP16 (438-490) monitored at 280 nM. Analytical sample was 
run in a water (with 0.1% TFA)/ acetonitrile system. The sample was injected with an isocratic 
flow of 50% water (with 0.1% TFA) and 50% acetonitrile. After 2 mins, the solvent gradient was 
increased from 10-50% acetonitrile over 40 mins.  
 
LC-MS of Ac-L2L3 VP16 (438-490) using an Agilent TOF. Samples were run in 50/50 0.1% 
TFA in water, and acetonitrile.  Samples were injected onto a C8 column with a C4 guard. 
Identity was confirmed under negative mode ionization conditions. 
 
Analytical HPLC trace of FITC-L2L3 VP16 (438-490) monitored at 280 nM. Analytical sample 
was run in a water (with 0.1% TFA)/ acetonitrile system. The sample was injected with an isocratic 
flow of 50% water (with 0.1% TFA) and 50% acetonitrile. After 2 mins, the solvent gradient was 
increased from 10-50% acetonitrile over 40 mins.  
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LC-MS of FITC-L2L3 VP16 (438-490) using an Agilent TOF. Samples were run in 50/50 0.1% 
TFA in water, and acetonitrile.  Samples were injected onto a C8 column with a C4 guard. 
Identity was confirmed under negative mode ionization conditions. 
 
 
Analytical HPLC trace of 4-DMN-L2L3 VP16 (438-490) monitored at 440 nM. Analytical sample 
was run in a water (with 0.1% TFA)/ acetonitrile system. The sample was injected with an isocratic 
flow of 50% water (with 0.1% TFA) and 50% acetonitrile. After 2 mins, the solvent gradient was 
increased from 10-50% acetonitrile over 40 mins.  
 
LC-MS of 4-DMN-L2L3 VP16 (438-490) using an Agilent TOF. Samples were run in 50/50 
0.1% TFA in water, and acetonitrile.  Samples were injected onto a C8 column with a C4 guard. 
Identity was confirmed under negative mode ionization conditions. 
 











Analytical HPLC trace of Ac-ATF6α (38-75) monitored at 280 nM. Analytical sample was run 
in a water (with 0.1% TFA)/ acetonitrile system. The sample was injected with an isocratic flow 
of 50% water (with 0.1% TFA) and 50% acetonitrile. After 2 mins, the solvent gradient was 
increased from 10-50% acetonitrile over 40 mins.  
 
LC-MS of Ac-ATF6α (38-75) using an Agilent TOF. Samples were run in 50/50 0.1% TFA in 
water, and acetonitrile.  Samples were injected onto a C8 column with a C4 guard. Identity was 
confirmed under negative mode ionization conditions. 
 
 
Analytical HPLC trace of FITC-ATF6α (38-75) monitored at 495 nM. Analytical sample was run 
in a water (with 0.1% TFA)/ acetonitrile system. The sample was injected with an isocratic flow 
of 50% water (with 0.1% TFA) and 50% acetonitrile. After 2 mins, the solvent gradient was 
increased from 10-50% acetonitrile over 40 mins.  
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LC-MS of FITC-ATF6α (38-75) using an Agilent TOF. Samples were run in 50/50 0.1% TFA 
in water, and acetonitrile.  Samples were injected onto a C8 column with a C4 guard. Identity 
was confirmed under negative mode ionization conditions. 
 
Analytical HPLC trace of 4-DMN-ATF6α (38-75) monitored at 440 nM. Analytical sample was 
run in a water (with 0.1% TFA)/ acetonitrile system. The sample was injected with an isocratic 
flow of 50% water (with 0.1% TFA) and 50% acetonitrile. After 2 mins, the solvent gradient was 
increased from 10-50% acetonitrile over 40 mins.  
 
LC-MS of 4-DMN-ATF6α (38-75) using an Agilent TOF. Samples were run in 50/50 0.1% TFA 
in water, and acetonitrile.  Samples were injected onto a C8 column with a C4 guard. Identity 
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